



**COVID-19 Living Evidence  
Synthesis #10**  
(Version 10.3: 2nd March 2022)

**Appendix 1: Summary of Included Studies**

*Note: Newly added studies in blue.*

Study ID	First author	Location	Population of interest	Total sample size	Vaccines included in report	Full schedule and/or booster data	Outcomes included in report	Number of follow-up time points	VOC specific data included in report
01-3	Andrews (1)	UK	Persons aged >16 years	52,333,72	BNT162b2 AZD1222 (ChAdOx1) *	Full schedule	Symptomatic cases Hospitalisations Deaths	at most 2	Delta
02-3	Bedston (2)	UK	HCWs aged ≥16 years	82,959	BNT162b2	Full schedule	Any cases	3	N/A
03-3	Britton (3)	USA	Adults aged ≥20 years	1,634,271	BNT162b2 mRNA-1273 Ad26.CoV2.S *	Full schedule	Symptomatic cases	at most 6	Delta
04-3	Bruxvoort (4)	USA	KPSC members aged ≥18 years	352,878 unvaccinated and 352,878 vaccinated	mRNA-1273	Full schedule	Any cases	3	Delta
05-3	Buchan (5)	Canada	Adults aged >18 years	134,435	BNT162b2 Ad26.CoV2.S AZD1222 (ChAdOx1)	Full schedule	Symptomatic cases	3	Delta Omicron

					mRNA-1273				
06-3	Cerqueira-Silva (6)	Brazil	Adults aged >18 years	30,910	BNT162b2, AZD1222 (ChAdOx1) Ad26.CoV2.S *	Full schedule	Symptomatic cases	1	N/A
07-2	Chemaitelly (7)	Qatar	Persons aged ≥12 years in Qatar	494,859	BNT162b2	Full schedule	All cases	At most 4	Delta
08-2	De Gier (8)	Netherlands	Persons aged ≥12 year in a nationwide registry of COVID-19 hospitalizations	15,571	BNT162b2 Ad26.CoV2.S AZD1222 (ChAdOx1) mRNA-1273	Full schedule	Hospitalisations	2	Delta
09-2	El Sahly (9)	USA	Adults aged ≥18 years with high risk for Covid-19	28,451	mRNA-1273	Full schedule	Symptomatic cases	1	N/A
10-3	Florea (10)	USA	KPSC members aged >18 years	1,854,008	mRNA-1273	Full schedule	All cases Hospitalisations	2	N/A
11-3	Katikireddi (11)	Scotland	Adults aged >18 years	2,534,527	AZD1222 (ChAdOx1)	Full schedule	Symptomatic cases	3	N/A

12-3	Lin (12)	USA	Adults aged ≥18 years in North Carolina	10,600,823	BNT162b2 Ad26.CoV2.S mRNA-1273 *	Full schedule	All cases Hospitalizations Deaths	3	N/A
13-3	Lytras (13)	Greece	Persons aged ≥15 years	9,200,000	BNT162b2 Ad26.CoV2.S AZD1222 (ChAdOx1) mRNA-1273 *	Full schedule	Deaths	1	N/A
14-3	Machado (14)	Portugal	Adults aged ≥65 years	471,439,909	BNT162b2 mRNA-1273	Full schedule	Symptomatic cases Hospitalizations Deaths	1	N/A
15-3	Nordstrom (15)	Sweden	Adults aged >18 years in Sweden	1,684,958	BNT162b2 AZD1222 (ChAdOx1) mRNA-1273*	Full schedule	All cases	At most 3	N/A
16-3	Petras (16)	Prague	Hospital staff aged ≥18 years	11,443	BNT162b2 Ad26.CoV2.S AZD1222 (ChAdOx1) mRNA-1273	Full schedule	All cases	1	N/A
17-3	Poukka (17)	Finland	HCWs aged 16-69 years	427,905	BNT162b2 AZD1222 (ChAdOx1) mRNA-1273	Full schedule	All cases Hospitalizations	1	Delta
18-3	Robles-Fontan (18)	Puerto Rico	Persons aged ≥12 years	540,140	BNT162b2 mRNA-1273 Ad26.CoV2.S *	Full schedule	All cases	2	N/A

19-3	Rosenberg (19)	USA	Adults aged ≥18 years in New York State	8,690,825	BNT162b2 mRNA-1273 AZD1222 (ChAdOx1) *	Full schedule	All cases Hospitalizations	1	N/A
20-2	Skowronski (20)	Canada	Adults aged >18 years in BC and QC	1,235,447 (380,532 BC; 854,915 QC)	BNT162b2 AZD1222 (ChAdOx1) mRNA-1273*	Full schedule	All cases Hospitalizations	At most 3	Delta
21-3	Tartof (21)	USA	KPSC members aged >18 years	3,436,957	BNT162b2	Full schedule	All cases Hospitalizations	4	N/A
22-1	Thomas (22)	Global	Persons aged ≥16 years	44,047	BNT162b2	Full schedule	All cases	1	N/A
23-1	Thompson (23)	USA	Adults aged ≥50 years	41,552 hospitalisations + 21,522 ED visits from 187 hospitals	BNT162b2 Ad26.CoV2.S mRNA-1273	Full schedule	Hospitalisations	1	N/A
24-3	Young-Xu (24)	USA	Male veterans aged ≥65 years	71,190	BNT162b2 mRNA-1273	Full schedule	All cases	At most 5	Delta
25-3	Ferdinands (25)	USA	Adults aged ≥18 years	241,204	BNT162b2 mRNA-1273	Full schedule and booster	Hospitalisations	2	Delta Omicron

26-3	Hall (26)	UK	Adult HCWs aged ≥18 years	35,768	BNT162b2 Ad26.CoV2.S AZD1222 (ChAdOx1) mRNA-1273	Full schedule	All cases	2	N/A
27-3	Chemaitelly (27)	Qatar	Persons aged ≥12 years in Qatar	84,884	BNT162b2	Full schedule and booster	Symptomatic cases	At most 9	Omicron

Legend: BC: British Columbia; HCWs: healthcare workers; PCR: Polymerase chain reaction test; QC: Quebec; RCT: randomized controlled trial; USA: United States of America; UK: United Kingdom; HCW: healthcare workers; KPSC: Kaiser permanente Southern California

\*Data are reported separately by vaccine.



## References

1. Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. *N Engl J Med*. 2022 Jan 27;386(4):340–50.
2. Bedston S, Akbari A, Jarvis CI, Lowthian E, Torabi F, North L, et al. COVID-19 vaccine uptake, effectiveness, and waning in 82,959 health care workers: A national prospective cohort study in Wales. *Vaccine*. 2022 Feb 16;40(8):1180–9.
3. Britton A, Fleming-Dutra KE, Shang N, Smith ZR, Dorji T, Derado G, et al. Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance. *JAMA* [Internet]. 2022 Feb 14 [cited 2022 Mar 2]; Available from: <https://doi.org/10.1001/jama.2022.2068>
4. Bruxvoort KJ, Sy LS, Qian L, Ackerson BK, Luo Y, Lee GS, et al. Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. *BMJ*. 2021 Dec 15;375:e068848.
5. Buchan SA, Chung H, Brown KA, Austin PC, Fell DB, Gubbay JB, et al. Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes [Internet]. *medRxiv*; 2022 [cited 2022 Mar 2]. p. 2021.12.30.21268565. Available from: <https://www.medrxiv.org/content/10.1101/2021.12.30.21268565v2>
6. Cerqueira-Silva T, Andrews JR, Boaventura VS, Ranzani OT, Oliveira V de A, Paixão ES, et al. Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COVS.2 among individuals with prior SARS-CoV-2 infection in Brazil [Internet]. *medRxiv*; 2021 [cited 2022 Mar 2]. p. 2021.12.21.21268058. Available from: <https://www.medrxiv.org/content/10.1101/2021.12.21.21268058v1>
7. Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. *N Engl J Med*. 2021 Oct 6;NEJMoa2114114.
8. de Gier B, Kooijman M, Kemmeren J, de Keizer N, Dongelmans D, van Iersel SCJL, et al. COVID-19 vaccine effectiveness against hospitalizations and ICU admissions in the Netherlands, April- August 2021 [Internet]. *Infectious Diseases (except HIV/AIDS)*; 2021 Sep [cited 2021 Nov 26]. Available from: <http://medrxiv.org/lookup/doi/10.1101/2021.09.15.21263613>
9. El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. *N Engl J Med*. 2021 Nov 4;385(19):1774–85.
10. Florea A, Sy LS, Luo Y, Qian L, Bruxvoort KJ, Ackerson BK, et al. Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study [Internet]. *medRxiv*; 2021 [cited 2022 Mar 2]. p. 2021.12.13.21267620. Available from: <https://www.medrxiv.org/content/10.1101/2021.12.13.21267620v2>
11. Katikireddi SV, Cerqueira-Silva T, Vasileiou E, Robertson C, Amele S, Pan J, et al. Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil. *The Lancet*. 2022 Jan 1;399(10319):25–35.
12. Lin D-Y, Gu Y, Wheeler B, Young H, Holloway S, Sunny S-K, et al. Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina. *New England Journal of Medicine*. 2022 Jan 12;0(0):null.

13. Lytras T, Kontopidou F, Lambrou A, Tsiodras S. Comparative effectiveness of COVID-19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaign [Internet]. medRxiv; 2022 [cited 2022 Mar 2]. p. 2022.01.28.22270009. Available from: <https://www.medrxiv.org/content/10.1101/2022.01.28.22270009v1>
14. Machado A, Kislaya I, Rodrigues AP, Sequeira D, Lima J, Cruz C, et al. COVID-19 vaccine effectiveness against laboratory confirmed symptomatic SARS-CoV-2 infection, COVID-19 related hospitalizations and deaths, among individuals aged 65 years or more in Portugal: a cohort study based on data-linkage of national registries February-September 2021 [Internet]. medRxiv; 2021 [cited 2022 Mar 2]. p. 2021.12.10.21267619. Available from: <https://www.medrxiv.org/content/10.1101/2021.12.10.21267619v1>
15. Nordström P, Ballin M, Nordström A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. *The Lancet*. 2022 Feb 26;399(10327):814–23.
16. Petráš M, Lesná IK, Večeřová L, Nyčová E, Malinová J, Klézl P, et al. The Effectiveness of Post-Vaccination and Post-Infection Protection in the Hospital Staff of Three Prague Hospitals: A Cohort Study of 8-Month Follow-Up from the Start of the COVID-19 Vaccination Campaign (COVANESS). *Vaccines*. 2022 Jan;10(1):9.
17. Poukka E, Baum U, Palmu AA, Lehtonen TO, Salo H, Nohynek H, et al. Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021. *Vaccine*. 2022 Jan 31;40(5):701–5.
18. Robles-Fontán MM, Irizarry RA. Effectiveness of different booster regimens for preventing infection and adverse outcomes in Puerto Rico [Internet]. medRxiv; 2021 [cited 2022 Mar 2]. p. 2021.12.19.21268070. Available from: <https://www.medrxiv.org/content/10.1101/2021.12.19.21268070v1>
19. Rosenberg ES, Dorabawila V, Easton D, Bauer UE, Kumar J, Hoen R, et al. Covid-19 Vaccine Effectiveness in New York State. *New England Journal of Medicine*. 2022 Jan 13;386(2):116–27.
20. Skowronski DM, Setayeshgar S, Febriani Y, Ouakki M, Zou M, Talbot D, et al. Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada [Internet]. *Infectious Diseases (except HIV/AIDS)*; 2021 Oct [cited 2021 Nov 26]. Available from: <http://medrxiv.org/lookup/doi/10.1101/2021.10.26.21265397>
21. Tartof SY, Slezak JM, Puzniak L, Hong V, Frankland TB, Ackerson BK, et al. Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study. *The Lancet Regional Health - Americas*. 2022 Feb 14;100198.
22. Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. *N Engl J Med*. 2021 Sep 15;NEJMoa2110345.
23. Thompson MG, Stenehjem E, Grannis S, Ball SW, Naleway AL, Ong TC, et al. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. *N Engl J Med*. 2021 Sep 8;NEJMoa2110362.
24. Young-Xu Y, Zwain GM, Powell EI, Smith J. Estimated Effectiveness of COVID-19 Messenger RNA Vaccination Against SARS-CoV-2 Infection Among Older Male Veterans Health Administration Enrollees, January to September 2021. *JAMA Network Open*. 2021 Dec 15;4(12):e2138975.

25. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning 2-Dose and 3-Dose effectiveness of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance—VISION Network, 10 States, August 2021–January 2022. 2022;
26. Hall V, Foulkes S, Insalata F, Kirwan P, Saei A, Atti A, et al. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. *New England Journal of Medicine*. 2022 Feb 16;0(0):null.
27. Chemaitelly H, Ayoub HH, AlMukdad S, Tang P, Hasan MR, Yassine HM, et al. Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar [Internet]. medRxiv; 2022 [cited 2022 Mar 2]. p. 2022.02.07.22270568. Available from: <https://www.medrxiv.org/content/10.1101/2022.02.07.22270568v1>



## Appendix 2: Details of meta-analyses

### Explanation on imputation

Meta-analyses were performed when studies provided vaccine effectiveness (VE), risk ratio (RR), odds risk (OR) or hazard ratio (HR) data with confidence intervals (CI) on cases, hospitalisations, or death for at least baseline (0-42 days since second dose of vaccine) and at least one follow-up time point ( $\geq 112$  days since complete primary series of a vaccine or  $\geq 84$  days since an additional dose of the vaccine). VE was converted to rate ratios and 95% CI, and adjusted (symmetrical) CIs were calculated based on original CIs with larger standard error. Mixed-effects models were used to calculate pooled effects given the anticipated heterogeneity across studies and group comparisons (follow-up time points). When information was available, sensitivity analyses were performed for: 1) type of vaccines (mRNA or adenovirus); 2) vaccine's brand ((i.e., AstraZeneca/COVISHIELD (AZD1222/ChAdOx1), Janssen (Johnson & Johnson: Ad26.COV2.S), Moderna (mRNA-1273) and Pfizer-BioNTech (BNT162b2)); and 3) VOC (Delta or Omicron). All analyses were performed using Comprehensive Meta Analysis (CMA) version 3.

### Appendix 3: Definitions and glossary

**Full vaccine series:** Receipt of one of the following COVID-19 vaccines authorised by Health Canada:

- Two dose of AstraZeneca/COVISHIELD (AZD1222/ChAdOx1), Moderna (mRNA-1273), or Pfizer-BioNTech (BNT162b2);
- One dose of Janssen (Johnson & Johnson: Ad26.COV2.S); or
- A combination of the above

**Fully vaccinated:** A person who is at least 14 days post having received one of the following vaccine schedules:

- the full series of a COVID-19 vaccine authorized by Health Canada (see above); or
- the full series of the above vaccines plus an additional dose in immunocompromised individuals

**Additional dose:** A person who has received:

- a full series of a COVID-19 vaccine authorised by Health Canada (see above) plus an additional dose of a COVID-19 vaccine authorised by Health Canada; or
- the full series of the above vaccines plus two additional doses in immunocompromised individuals

**Confirmed infection:** A person with confirmation of infection with SARS-CoV-2 documented by the detection of at least 1 specific gene target by a validated laboratory-based nucleic acid amplification test (NAAT) assay (e.g. real-time PCR or nucleic acid sequencing) performed at a community, hospital, or reference laboratory (the National Microbiology Laboratory or a provincial public health laboratory).(2)

**Symptomatic illness:** A person with confirmation of SARS-CoV-2 infection, presenting symptoms that vary in type, frequency, and severity. The most common symptoms include fever, chills, new or worsening cough, fatigue, headache, and gastrointestinal symptoms.(3)

**Asymptomatic infection:** A person with confirmation of SARS-CoV-2 infection but with no presentation of symptoms in the course of the disease.

**Hospitalisation due to COVID-19:** Inpatient admission to a hospital and/or ICU unit, associated with laboratory-confirmed SARS-CoV-2 infection.

**Death due to COVID-19:** Death resulting from a clinically compatible illness in a probable or confirmed COVID-19 case, with no presence of clear alternative causes unrelated to COVID-19 (e.g., trauma, poisoning, drug overdose).

**Variants of concern (VOC):** A SARS-CoV-2 variant is considered a VOC in Canada based on a set of criteria including increased transmissibility or detrimental change in COVID-19 epidemiology, increased virulence, decreased effectiveness of vaccines, and so on. As of August 05, 2021, Canada has designated the following SARS-CoV-2 variants as VOCs: Alpha (B.1.1.7), Beta (B.1.351, B.1.351.1., B.1.351.2, B.1.351.3, B.1.351.4), Gamma (P.1, P.1.1, P.1.2), and Delta (B.1.617.2, AY.1, AY.2, AY.3, AY.3.1).(4)

**Vaccine effectiveness (VE):** A measure of how well a vaccine protects people from getting the outcome of interest in real-world practice (For example: VE of 92% against infection means that 92% of people will be protected from becoming infected with COVID and 8% of people will still be at risk of becoming infected with COVID). In the context of the current report, we have utilised the term vaccine effectiveness to cover all studies. However, we are aware that the studies that have been included range from efficacy through to effectiveness studies. We decided to use this terminology as it is consistent with how most evidence synthesis products describe these studies. To be consistent with this, in the French summary we have utilised the term

efficacité, and it is noted that in French there is no distinction between the translations of efficacy and effectiveness.

**AZ:** AstraZeneca

**CIs:** Confidence Intervals

**Delta:** variant of concern B.1.617.2

**HCW:** Healthcare workers

**LTC:** Long-term care

**LTCF:** Long-term care facility

**MOD:** Moderna

**Obs:** observational study

**Omicron:** variant of concern B.1.1.529

**OR:** odds ratio

**PF:** Pfizer

**RCT:** Randomized controlled trial

**UK:** United Kingdom

**USA:** United States of America

**VOI:** variant of interest

**WHO:** World Health Organization

#### **Appendix 4: Critical appraisal process**

We appraised the quality of the individual studies using an adapted version of ROBINS-I. This tool classifies the Risk of Bias of a study as **Low, Moderate, Serious, Critical, or No Information**. *Low Risk of Bias indicates High Quality, and Critical Risk of Bias indicates Very Low (insufficient) Quality*. ROBINS-I appraises 7 bias domains and judges each study against an ideal reference randomised controlled trial. To improve the utility of ROBINS-I for assessing studies reporting vaccine effectiveness, we have focused on study characteristics that introduce bias as reported in the vaccine literature (see WHO. Evaluation of COVID-19 vaccine effectiveness. Interim Guidance. 17 March 2021). An overall judgement of “serious” or “critical” is given when the study is judged to be at critical risk of bias in at least one domain. Three or more serious risk of bias domains is given an overall risk of bias of critical.

## Appendix 5: Excluded Studies

Author	Title	Journal	Reason for exclusion
Abbasi	COVID-19 mRNA Vaccines Blunt Breakthrough Infection Severity	JAMA - Journal of the American Medical Association	wrong intervention
Abbasi	Oldest Adults Need 2 mRNA Vaccine Doses to Neutralize SARS-CoV-2	JAMA - Journal of the American Medical Association	wrong publication type
Abdool Karim & de Oliveira	New SARS-CoV-2 variants - Clinical, public health, and vaccine implications	New England Journal of Medicine	wrong intervention
Absalon et al.	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Reply	The New England Journal of Medicine	wrong intervention
Abu Raddad et al.	Effectiveness of BNT162b2 and mRNA-1273 COVID-19 boosters against SARS-CoV-2 Omicron (B.1.1.529) infection in Qatar	medRxiv	wrong outcome
Abu Raddad et al.	Waning of mRNA-1273 vaccine effectiveness against SARS-CoV-2 infection in Qatar		delayed exclusion - this is a letter of correspondence that refers to an original study
Abu Raddad et al.	Effect of vaccination and of prior infection on infectiousness of vaccine breakthrough infections and reinfections	Preprint - medRxiv	wrong outcome
Abu Raddad et al.	Protection afforded by the BNT162b2 and mRNA-1273 COVID-19 vaccines in fully vaccinated cohorts with and without prior infection	Preprint - medRxiv	wrong intervention
Abu Raddad et al.	Protection offered by mRNA-1273 versus BNT162b2 vaccines against SARS-CoV-2 infection and severe COVID-19 in Qatar	medRxiv	wrong comparator
Abu-Raddad et al.	Protection offered by mRNA-1273 versus BNT162b2 vaccines against SARS-CoV-2 infection and severe COVID-19 in Qatar	medRxiv	wrong comparator
Abu-Raddad et al.	Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants	The New England Journal of Medicine	wrong intervention
Abu-Raddad et al.	Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses	Journal of Travel Medicine	wrong intervention
Abu-Sinni et al.	COVID-19 vaccine - Long term immune decline and breakthrough infections	Vaccine	wrong comparator
Ackland et al.	Evolution of case fatality rates in the second wave of coronavirus in England: effects of false positives, a Variant of Concern and vaccination	Preprint - medRxiv	wrong intervention
Adhikari & Spong	COVID-19 Vaccination in Pregnant and Lactating Women	JAMA - Journal of the American Medical Association	wrong study design
Adibi et al.	Continuing COVID-19 Vaccination of Front-Line Workers in British Columbia with the	Preprint - medRxiv	wrong outcome

	AstraZeneca Vaccine: Benefits in the Face of Increased Risk for Prothrombotic Thrombocytopenia		
Al Qahtani et al.	Morbidity and mortality from COVID-19 post-vaccination breakthrough infections in association with vaccines and the emergence of variants in Bahrain	Preprint - Research Square	wrong intervention
Alali et al.	Effectiveness of BNT162b2 and ChAdOx1 Vaccines against Symptomatic COVID-19 among Healthcare Workers in Kuwait: A Retrospective Cohort Study	Healthcare (Basel, Switzerland)	wrong outcome
Alali et al.	Effectiveness of BNT162b2 and ChAdOx1 vaccines against symptomatic COVID-19 among Healthcare Workers in Kuwait: A retrospective cohort study	Preprint - medRxiv	wrong intervention
Albach et al.	Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response	Annals of the Rheumatic Diseases	wrong study design
Aldridge et al.	Waning of SARS-CoV-2 antibodies targeting the Spike protein in individuals post second dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and risk of breakthrough infections: analysis of the Virus Watch community cohort	medRxiv	wrong comparator
Alencar et al.	High Effectiveness of SARS-CoV-2 Vaccines in Reducing COVID-19-Related Deaths in over 75-Year-Olds, Ceara State, Brazil	Tropical Medicine and Infectious Disease	wrong intervention
Alholm et al.	SARS-CoV-2 vaccination in gynecologic oncology	European Journal of Gynaecological Oncology	wrong publication type
Ali et al.	Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents	The New England Journal of Medicine	wrong intervention
Alkhafaji et al.	The Impact of COVID-19 Vaccine on Rate of Hospitalization and Outcome of COVID-19 Infection in a Single Center in the Eastern Province of Saudi Arabia	Research Square	wrong population
Allen et al.	Comparative transmission of SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants and the impact of vaccination: national cohort study, England	medRxiv	wrong study duration
Alroy-Preis et al.	Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data	The Lancet	wrong intervention
Altmann et al.	Immunity to SARS-CoV-2 variants of concern	Science	wrong publication type
Amatya et al.	COVID-19 in fully vaccinated Everest trekkers in Nepal	Journal of Travel Medicine	wrong study design

Amirthalingam et al.	Higher serological responses and increased vaccine effectiveness demonstrate the value of extended vaccine schedules in combating COVID-19 in England	Preprint - medRxiv	wrong intervention
Amit et al.	COVID-19 vaccine efficacy data: solid enough to delay second dose? - Authors' reply	The Lancet	wrong study design
Amit et al.	Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients	The Lancet	wrong intervention
Amodio et al.	Effectiveness of mRNA COVID-19 vaccination against SARS-CoV-2 infection and COVID-19 disease in Sicily over an eight-month period	SSRN	delayed exclusion - unvaccinated group include single-dose and non mRNA vaccines
Andeweg et al.	Protection of COVID-19 vaccination and previous infection against Omicron BA.1 and Delta SARS-CoV-2 infections, the Netherlands, 22 November 2021- 19 January 2022	medRxiv	wrong study duration
Andrejko et al.	Prevention of COVID-19 by mRNA-based vaccines within the general population of California	Clinical Infectious Diseases	wrong intervention
Andrejko et al.	Early evidence of COVID-19 vaccine effectiveness within the general population of California	Hand search; Preprint - medRxiv	wrong intervention
Andrews et al.	Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern	medRxiv	duplicate
Andrews et al.	Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern	medRxiv	wrong comparator
Andrews et al.	Effectiveness of COVID-19 booster vaccines against covid-19 related symptoms, hospitalisation and death in England	Nature medicine	wrong comparator
Angel et al.	Association between Vaccination with BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections among Health Care Workers	JAMA - Journal of the American Medical Association	wrong intervention
Anjan et al.	Breakthrough COVID-19 infections after mRNA vaccination in Solid Organ Transplant Recipients in Miami, Florida	Transplantation	wrong intervention
Anonymous	Exam 2: Effectiveness of SARS-CoV-2 vaccination in a Veterans Affairs Cohort of Inflammatory Bowel Disease Patients with Diverse Exposure to Immunosuppressive Medications	Gastroenterology	wrong publication type
Aran	Estimating real-world COVID-19 vaccine effectiveness in Israel	Preprint - medRxiv	wrong intervention
Arbel et al.	How many lives do COVID vaccines save? Evidence from Israel	American journal of infection control	wrong study design
Arbel et al.	How many lives do COVID vaccines save? Evidence from Israel	medRxiv	wrong comparator
Arnold et al.	Are vaccines safe in patients with Long COVID? A prospective observational study	Preprint - medRxiv	wrong intervention

Aslam et al.	COVID-19 vaccination is protective of clinical disease in solid organ transplant recipients	Transplant infectious disease : an official journal of the Transplantation Society	wrong comparator
Auvigne et al.	Serious hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants: an exposed-unexposed cohort study in December 2021 from the COVID-19 surveillance databases in France	medRxiv	wrong study duration
Azamgarhi et al.	BNT162b2 vaccine uptake and effectiveness in UK healthcare workers - a single centre cohort study	Nature Communications	wrong intervention
Baden et al.	Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine	New England Journal of Medicine	wrong intervention
Baden et al.	Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge	medRxiv	wrong intervention
Bahl et al.	Vaccination reduces need for emergency care in breakthrough COVID-19 infections: A multicenter cohort study	Preprint - medRxiv	wrong intervention
Bailly et al.	BNT162b2 mRNA vaccination did not prevent an outbreak of SARS COV-2 variant 501Y.V2 in an elderly nursing home but reduced transmission and disease severity	Clinical Infectious Diseases	wrong intervention
Bajema et al.	Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021	MMWR. Morbidity and mortality weekly report	wrong comparator
Bajema et al.	Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalization - Five Veterans Affairs Medical Centers, United States, February 1-August 6, 2021	MMWR. Morbidity and mortality weekly report	wrong outcome
Balicer et al.	Effectiveness of the BNT162b2 mRNA COVID-19 Vaccine in Pregnancy	Preprint – Research Square	wrong intervention
Baltas et al.	Post-vaccination COVID-19: A case-control study and genomic analysis of 119 breakthrough infections in partially vaccinated individuals	Clinical Infectious Diseases	wrong intervention
Banon et al.	BNT162b2 Messenger RNA COVID-19 Vaccine Effectiveness in Patients With Inflammatory Bowel Disease: Preliminary Real-World Data During Mass Vaccination Campaign	Gastroenterology	uplicated
Bar On et al.	BNT162b2 vaccine booster dose protection: A nationwide study from Israel	Preprint - medRxiv	wrong intervention
Bar-On et al.	Protection of BNT162b2 vaccine booster against Covid-19 in Israel	New England Journal of Medicine	wrong comparator



Barbosa et al.	High effectiveness of sars-cov-2 vaccines in reducing covid-19-related deaths in over 75-year-olds, Ceara State, Brazil	Tropical Medicine and Infectious Disease	duplicated
Barda et al.	Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study	The Lancet	wrong comparator
Barlow et al.	Effectiveness of COVID-19 Vaccines Against SARS-CoV-2 Infection During a Delta Variant Epidemic Surge in Multnomah County, Oregon, July 2021	Preprint - medRxiv	wrong intervention
Barnabas et al.	A Public Health COVID-19 Vaccination Strategy to Maximize the Health Gains for Every Single Vaccine Dose	Annals of Internal Medicine	wrong outcome
Barrière et al.	Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors	Annals of Oncology	wrong outcome
Barros et al.	Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality	EClinicalMedicine	duplicated
Baum et al.	Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation among Finnish elderly and chronically ill-An interim analysis of a nationwide cohort study	PloS one	wrong comparator
Baum et al.	Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalization among Finnish elderly and chronically ill—An interim analysis of a nationwide cohort study	Preprint - medRxiv	wrong intervention
Belmin et al.	First-Dose Coronavirus 2019 Vaccination Coverage among the Residents of Long-Term Care Facilities in France	Gerontology	wrong outcome
Ben Dov et al.	Impact of tozinameran (BNT162b2) mRNA vaccine on kidney transplant and chronic dialysis patients: 3-5 months followup	medRxiv	delayed exclusion - data mainly focusing on immunogenicity findings
Ben-Aharon et al.	15590 Efficacy and toxicity of BNT162b2 vaccine in cancer patients	Annals of Oncology	duplicated
Ben-Tov et al.	BNT162b2 Messenger RNA COVID-19 Vaccine Effectiveness in Patients With Inflammatory Bowel Disease: Preliminary Real-World Data During Mass Vaccination Campaign	Gastroenterology	wrong intervention
Benenson et al.	BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers	The New England Journal of Medicine	wrong intervention
Benjamini et al.	Safety and efficacy of BNT162b mRNA Covid19 Vaccine in patients with chronic lymphocytic leukemia	Haematologica	wrong outcome

Benotmane et al.	Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine	Kidney International	wrong outcome
Benotmane et al.	Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients	Kidney International	wrong outcome
Berec et al.	Real-life protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in the Czech Republic: A whole country retrospective view	medRxiv	wrong comparator
Berec et al.	Real-life protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in the Czech Republic: A whole country retrospective view	medRxiv	delayed exclusion - baseline is calculated 0-2 months after 14 days post-receipt of second dose, which is beyond our 30.5 days average post-receipt of second dose threshold
Bergwerk et al.	Covid-19 Breakthrough Infections in Vaccinated Health Care Workers	The New England Journal of Medicine	wrong outcome
Bermingham et al.	Estimating the effectiveness of first dose of COVID-19 vaccine against mortality in England: a quasi-experimental study	Preprint - medRxiv	wrong intervention
Bernal et al.	Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England	Preprint - medRxiv	wrong intervention
Bernal et al.	Effectiveness of BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on mortality following COVID-19	Preprint - medRxiv	wrong intervention
Bernal et al.	Effectiveness of COVID-19 vaccines against the B.1.617.2 variant	The New England Journal of Medicine	wrong intervention
Bhattacharya et al.	Evaluation of the dose-effect association between the number of doses and duration since the last dose of COVID-19 vaccine, and its efficacy in preventing the disease and reducing disease severity: A single centre, cross-sectional analytical study from India	Diabetes and Metabolic Syndrome: Clinical Research and Reviews	wrong study design
Bianchi et al.	BNT162b2 mRNA COVID-19 vaccine effectiveness in the prevention of SARS-CoV-2 Infection: A preliminary report	Journal of Infectious Diseases	wrong intervention
Bianchi et al.	BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in Five-Month Follow-Up: A Retrospective Cohort Study	Vaccines	wrong outcome
Bianchi et al.	BNT162b2 mRNA COVID-19 vaccine effectiveness in the prevention of SARS-CoV-2 Infection: A preliminary report	SSRN	delayed exclusion - K-M plot included the 14 days before full vaccination - the correct FUP is non-extractable (figure 1)

Bird et al.	Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma	The Lancet Haematology	wrong intervention
Bjork et al.	Effectiveness of the BNT162b2 vaccine in preventing COVID-19 in the working age population - first results from a cohort study in Southern Sweden	Preprint - medRxiv	wrong intervention
Bjork et al.	High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population-first results from a cohort study in Southern Sweden	Infectious Diseases	uplicated
Blain et al.	Receptor binding domain-IgG levels correlate with protection in residents facing SARS-CoV-2 B.1.1.7 outbreaks	Allergy	wrong intervention
Blaiszik et al.	The Delta Variant Had Negligible Impact on COVID-19 Vaccine Effectiveness in the USA	medRxiv	wrong study design
Bleicher et al.	Early exploration of COVID-19 vaccination safety and effectiveness during pregnancy: interim descriptive data from a prospective observational study	Vaccine	wrong outcome
Bliden et al.	Evolution of Anti-SARS-CoV-2 IgG Antibody and IgG Avidity Post Pfizer and Moderna mRNA Vaccinations	Preprint - medRxiv	wrong outcome
Bobdey et al.	Effectiveness of ChAdOx1 nCoV-19 Vaccine: Experience of a tertiary care institute	Medical Journal Armed Forces India	wrong intervention
Bollineni et al.	Characteristics and outcomes among vaccinated lung transplant patients with breakthrough COVID-19	Transplant infectious disease : an official journal of the Transplantation Society	wrong outcome
Bongiovanni et al.	Evaluation of the immune response to COVID-19 vaccine mRNA BNT162b2 and correlation with previous COVID-19 infection	Journal of Clinical Virology	wrong outcome
Bookstein Peretz et al.	Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine	Ultrasound in Obstetrics & Gynecology	wrong intervention
Bouton et al.	COVID-19 vaccine impact on rates of SARS-CoV-2 cases and post vaccination strain sequences among healthcare workers at an urban academic medical center: a prospective cohort study	Preprint - medRxiv	wrong outcome
Bouton et al.	Coronavirus Disease 2019 Vaccine Impact on Rates of Severe Acute Respiratory Syndrome Coronavirus 2 Cases and Postvaccination Strain Sequences Among Health Care Workers at an Urban Academic Medical Center: A Prospective Cohort Study	Open forum infectious diseases	wrong intervention
Boyarsky et al.	Antibody response to 2-dose sars-cov-2 mrna vaccine series in solid organ transplant recipients	JAMA - Journal of the American Medical Association	wrong intervention

Braeye et al.	Vaccine effectiveness against infection and onwards transmission of COVID-19: Analysis of Belgian contact tracing data, January-June 2021	Vaccine	wrong intervention
Brinkley-Rubinstein et al.	Breakthrough SARS-CoV-2 Infections in Prison after Vaccination	The New England Journal of Medicine	wrong intervention
Britton et al.	Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance	JAMA	already assessed
Brosh-Nissimov et al.	BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel	Clinical Microbiology and Infection	wrong outcome
Brouqui et al.	COVID-19 re-infection	European Journal of Clinical Investigation	wrong intervention
Brunelli et al.	Comparative Effectiveness of mRNA-Based BNT162b2 Vaccine versus Adenovirus Vector-Based Ad26.COVS Vaccine for Prevention of COVID-19 among Dialysis Patients	Journal of the American Society of Nephrology : JASN	wrong comparator
Brunner et al.	Comparison of Antibody Response Durability of mRNA-1273, BNT162b2, and Ad26.COVS SARS-CoV-2 Vaccines in Healthcare Workers	New England Journal of Medicine	wrong outcome
Brunner et al.	SARS-CoV-2 Postvaccination Infections Among Staff Members of a Tertiary Care University Hospital—Vienna, January-July 2021; an Exploratory Study on 8 500 Employees with Better Outcome of Vector than m-RNA Vaccine	Preprint - SSRN	wrong intervention
Bruxvoort et al.	Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study	BMJ (Clinical research ed.)	wrong comparator
Bruxvoort et al.	Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study	Lancet Regional Health. Americas	wrong outcome
Bruxvoort et al.	Effectiveness of mRNA-1273 against Delta, Mu, and other emerging variants	medRxiv	delayed exclusion - baseline VE assessed at 14-60 (below our 30-day threshold)
Buchan et al.	Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes	medRxiv	wrong comparator
Buchan et al.	Effectiveness of COVID-19 vaccines against Omicron or Delta infection	medRxiv	delayed exclusion - study ID 05-3 is a more recent version of this study
Bukhari et al.	Real-World Effectiveness of COVID-19 Vaccines: the Diverging Pattern of COVID-19 Cases and Deaths in Countries with High Vaccination Rates	Preprint - SSRN	wrong intervention

Buonfrate et al.	Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study	Clinical Microbiology and Infection	wrong intervention
Burd et al.	The Israeli study of Pfizer BNT162b2 vaccine in pregnancy: Considering maternal and neonatal benefits	Journal of Clinical Investigation	wrong publication type
Butt et al.	Real-world Effectiveness of the SARS-CoV-2 mRNA Vaccines in Preventing Confirmed Infection in Patients on Chronic Hemodialysis	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America	wrong study duration
Butt et al.	Effectiveness of the SARS-CoV-2 mRNA Vaccines in Pregnant Women	Preprint - Research Square	wrong intervention
Butt et al.	Outcomes among patients with breakthrough SARS-CoV-2 infection after vaccination in a high-risk national population	EClinicalMedicine	wrong intervention
Butt et al.	Rate and risk factors for breakthrough SARS-CoV-2 infection after vaccination	The Journal of Infection	wrong intervention
Butt et al.	SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting	Annals of Internal Medicine	wrong intervention
Butt et al.	SARS-CoV-2 vaccine effectiveness in preventing confirmed infection in pregnant women	The Journal of clinical investigation	wrong study duration
Cabezas et al.	Effects of BNT162b2 mRNA Vaccination on COVID-19 Disease, Hospitalisation and Mortality in Nursing Homes and Healthcare Workers: A Prospective Cohort Study Including 28,594 Nursing Home Residents, 26,238 Nursing Home Staff, and 61,951 Healthcare Workers in Catalonia	Hand search; Preprint - SSRN	duplicated
Cabezas et al.	Effects of BNT162b2 mRNA Vaccination on COVID-19 Disease, Hospitalisation and Mortality in Nursing Homes and Healthcare Workers: A Prospective Cohort Study Including 28,594 Nursing Home Residents, 26,238 Nursing Home Staff, and 61,951 Healthcare Workers in Catalonia	Preprint - SSRN	wrong intervention
Cabezas, et al.	Associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with covid-19 in nursing homes and healthcare workers in Catalonia: Prospective cohort study	BMJ	delayed exclusion - prospective cohort evaluated VE data among nursing home residents, nursing home staff, and healthcare workers. Incidence rates, and adjusted hazard ratios for covid-19 infection according to vaccination status in study population is presented in Table 2 (but no information of individual level follow up; the

			authors presented only Exposure person days). Kaplan-Meier estimates of COVID infection according to vaccination status in study population is presented visually in Figure 3 (but no extractable information presented).
Callaghan et al.	Real-world Effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S Vaccines Against SARS-CoV-2 in Solid Organ and Islet Transplant Recipients	Transplantation	wrong outcome
Carazo et al.	Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada	Preprint - medRxiv	wrong intervention
Carazo et al.	Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America	duplicated
Cardona et al.	<p>SARS-CoV-2 Vaccinated Breakthrough Infections With Fatal and Critical Outcomes in the Department of Antioquia, Colombia</p>	Research Square	wrong outcome
Carrera et al.	How well do hemodialysis patients respond to the BNT162b2 mRNA COVID-19 vaccine	Journal of the American Society of Nephrology	wrong intervention
Cerqueira Silva et al.	Influence of age on the effectiveness and duration of protection in Vaxzevria and CoronaVac vaccines	Preprint - medRxiv	wrong intervention
Cerqueira-Silva et al.	Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil	Nature Medicine	already assessed
Cerqueira-Silva et al.	Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study	Lancet Regional Health. Americas	wrong intervention
Chadeau Hyam et al.	REACT-1 round 15 final report: Increased breakthrough SARS-CoV-2 infections among adults who had received two doses of vaccine, but booster doses and first doses in children are providing important protection	medRxiv	wrong comparator
Chadeau Hyam et al.	REACT-1 study round 14: High and increasing prevalence of SARS-CoV-2 infection among school-aged children during September 2021 and vaccine effectiveness against infection in England	medRxiv	wrong comparator
Chadeau-Hyam et al.	SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys	The Lancet. Respiratory medicine	wrong comparator

Chagla	The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 $\geq 7$ days after the 2nd dose	Annals of Internal Medicine	wrong intervention
Charles Pon Ruban et al.	Effectiveness of vaccination in preventing severe SARS CoV-2 infection in South India-a hospital-based cross-sectional study	medRxiv	wrong study design
Charmet et al.	Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France	The Lancet Regional Health-Europe	wrong intervention
Chauhan et al.	SARS-CoV-2 Vaccine-Induced Antibody Response and Reinfection in Persons with Past Natural Infection	Preprint - medRxiv	wrong intervention
Chemaitelly et al.	Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar	medRxiv	already assessed
Chemaitelly et al.	mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar	Hand search; Nature Medicine	wrong intervention
Chemaitelly et al.	Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses	Journal of Travel Medicine	duplicated
Chemaitelly et al.	MRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar.	Nature Medicine	wrong intervention
Chen et al.	Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint	BMC medicine	wrong intervention
Chin et al.	Effectiveness of COVID-19 vaccines among incarcerated people in California state prisons: retrospective cohort study	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America	wrong study design
Chin et al.	Effectiveness of COVID-19 Vaccines among Incarcerated People in California State Prisons: A Retrospective Cohort Study	Preprint - medRxiv	wrong intervention
Chin et al.	Effectiveness of the mRNA-1273 Vaccine during a SARS-CoV-2 Delta Outbreak in a Prison	The New England journal of medicine	wrong outcome
Chodick et al.	The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data	Clinical Infectious Diseases	wrong intervention
Christie et al.	Decreases in COVID-19 Cases, Emergency Department Visits, Hospital Admissions, and Deaths Among Older Adults Following the Introduction of COVID-19 Vaccine - United States, September 6, 2020-May 1, 2021	MMWR. Morbidity and mortality weekly report	wrong population

Chung et al.	Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: Test negative design study	The BMJ	wrong intervention
Clemens et al.	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil; an exploratory analysis of a randomised controlled trial	Preprint - Research Square	wrong intervention
Clemens et al.	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil	Nature communications	duplicated
Clifford et al.	Effectiveness of BNT162b2 and ChAdOx1 against SARS-CoV-2 household transmission: a prospective cohort study in England	medRxiv	wrong comparator
Coggiola et al.	SARS-CoV-2 infection: efficacy of extensive vaccination of the healthcare workforce in a large Italian hospital	La Medicina del lavoro	wrong study design
Cohen et al.	Comparative Efficacy over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine	Research Square	wrong comparator
Cohn et al.	SARS-CoV-2 vaccine protection and deaths among US veterans during 2021	Science	wrong comparator
Cohn et al.	Breakthrough SARS-CoV-2 infections in 620,000 US Veterans, February 1, 2021 to August 13, 2021	medRxiv	wrong intervention
Consonni et al.	Effectiveness of BNT162b2 COVID-19 vaccine among healthcare workers of a large hospital, Milan, Italy	Safety and Health at Work	already assessed
Consonni et al.	Effectiveness of COVID-19 vaccine in health care workers, Milan, Italy	Occupational and Environmental Medicine	Full text unavailable
Cook et al.	Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases	Preprint - medRxiv	wrong outcome
Corchado Garcia et al.	Real-world effectiveness of Ad26.COV2.S adenoviral vector vaccine for COVID-19	Preprint - medRxiv	wrong intervention
Corchado-Garcia et al.	Real-world effectiveness of Ad26. COV2. S adenoviral vector vaccine for COVID-19	SSRN	wrong study duration
Corchado-Garcia et al.	Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19	JAMA network open	wrong outcome
Corrao et al.	Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy	The Lancet. Infectious diseases	already assessed
Corrao et al.	Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since	The Lancet. Infectious diseases	wrong comparator



	vaccine completion: a retrospective observational analysis in Lombardy, Italy		
Corrao et al.	Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy	The Lancet Infectious Diseases	delayed exclusion - definition of unvaccinated group is unclear
Cox et al.	An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status	Clinical Infectious Diseases	duplicate
Dagan et al.	BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting	The New England Journal of Medicine	wrong intervention
Dagan et al.	Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy	Nature Medicine	wrong intervention
Dahlem et al.	Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients	Journal of the American Society of Nephrology	duplicate
Danthu et al.	Humoral Response after SARS-Cov-2 mRNA Vaccine in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients	Journal of the American Society of Nephrology: JASN	wrong intervention
Das et al.	Relation of vaccination with severity, oxygen requirement and outcome of COVID-19 infection in Chattogram, Bangladesh	Preprint - medRxiv	wrong intervention
Dash et al.	Breakthrough SARS-CoV-2 infections in an eastern state of India: A preliminary report	Preprint - Research Square	wrong outcome
Dashdorj et al.	Direct Comparison of Antibody Responses to Four SARS-CoV-2 Vaccines in Mongolia	Preprint - medRxiv	wrong outcome
Deiana et al.	Impact of Full Vaccination with mRNA BNT162b2 on SARS-CoV-2 Infection: Genomic and Subgenomic Viral RNAs Detection in Nasopharyngeal Swab and Saliva of Health Care Workers	Microorganisms	wrong outcome
Dickerman et al.	Comparative effectiveness of BNT162B2 and mRNA-1273 vaccines in U.S. Veterans	New England Journal of Medicine	wrong comparator
Domi et al.	The BNT162b2 vaccine is associated with lower new COVID-19 cases in nursing home residents and staff	Journal of the American Geriatrics Society	wrong intervention
Donadio et al.	Asymptomatic COVID-19 cases among older patients despite BNT162b2 vaccination: A case series in a geriatric rehabilitation ward during an outbreak	The Journal of Infection	wrong intervention
Drawz et al.	Effectiveness of BNT162b2 and mRNA-1273 Second Doses and Boosters for SARS-CoV-2 infection and SARS-CoV-2 Related Hospitalizations: A Statewide Report from the Minnesota Electronic Health Record Consortium	medRxiv	wrong comparator
Drawz et al.	Effectiveness of BNT162b2 and mRNA-1273 Second Doses and Boosters for SARS-CoV-2	Clinical infectious diseases : an official	wrong comparator

	infection and SARS-CoV-2 Related Hospitalizations: A Statewide Report from the Minnesota Electronic Health Record Consortium	publication of the Infectious Diseases Society of America	
Du Plessis et al.	Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant	New England Journal of Medicine	uplicated
Dulovic et al.	Diminishing immune responses against variants of concern in dialysis patients four months after SARS-CoV-2 mRNA vaccination	Preprint - medRxiv	wrong outcome
Ebinger et al.	Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2	Nature Medicine	wrong intervention
Ebinger et al.	Prior COVID-19 Infection and Antibody Response to Single Versus Double Dose mRNA SARS-CoV-2 Vaccination	Preprint - medRxiv	wrong outcome
Edelstein et al.	BNT 13b2 Pfizer vaccine protects against SARS-CoV-2 respiratory mucosal colonization even after prolonged exposure to positive family members	The Journal of Hospital Infection	wrong outcome
Efrati et al.	Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations	Scientific Reports	wrong outcome
Ella et al.	Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial	Preprint - medRxiv	wrong intervention
Elliott et al.	Rapid increase in Omicron infections in England during December 2021: REACT-1 study	Rapid increase in Omicron infections in England during December 2021: REACT-1 study	wrong outcome
Elliott et al.	REACT-1 round 13 final report: exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with Delta variant in England during May to July 2021	Hand search; Preprint - medRxiv	wrong intervention
Emary et al.	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial	The Lancet	wrong intervention
Embi et al.	Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-Nine States, January-September 2021	American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons	wrong outcome
Embi et al.	Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among	MMWR. Morbidity and mortality weekly report	wrong study duration

	Immunocompromised Adults - Nine States, January-September 2021		
Emborg et al.	Vaccine effectiveness of the BNT162b2 mRNA COVID-19 vaccine against RT-PCR confirmed SARS-CoV-2 infections, hospitalisations and mortality in prioritised risk groups	Preprint - medRxiv	wrong intervention
Epaulard et al.	Symptoms and severity in vaccinated and unvaccinated patients hospitalised with SARS-CoV-2 delta (B.1.617.2) variant infection	medRxiv	wrong comparator
Espi et al.	A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis	Kidney international	wrong outcome
Espi et al.	Justification, safety, and efficacy of a third dose of mRNA vaccine in maintenance hemodialysis patients: a prospective observational study	Preprint - medRxiv	wrong outcome
Eyre et al.	The impact of SARS-CoV-2 vaccination on Alpha & Delta variant transmission. medRxiv 2021	Preprint].[Google Scholar]	wrong study duration
Fabiani et al.	Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study	BMJ (Clinical research ed.)	wrong comparator
Fabiani et al.	Effectiveness of the comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021	Eurosurveillance	wrong intervention
Fabiani et al.	Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021	Eurosurveillance	wrong intervention
Falsey et al.	Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine	The New England journal of medicine	wrong study duration
Farah et al.	Effectiveness of Pfizer-BioNTech Vaccine Against COVID-19 Associated Hospitalizations among Lebanese Adults ,â•75 years- Lebanon, April-May 2021	medRxiv	wrong outcome
Faria et al.	Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) - preliminary report	Preprint - medRxiv	wrong intervention
Felip et al.	1591P Immune response after vaccination against SARS-COV-2 in lung cancer (LC) patients (p). Prospective study in the Medical Oncology Department at the Catalan Institute of Oncology-Badalona, Spain: COVID-lung vaccine	Annals of Oncology	wrong outcome

Feng et al.	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection	Preprint - medRxiv	wrong outcome
Fernando et al.	Neutralizing SARS-CoV-2 Antibody Response and Protective Effect of 2 Doses of ChAdOx1 nCoV-19 and BBV152 Vaccines in hemodialysis Patients: A Preliminary Report	Kidney International Reports	wrong outcome
Firinu et al.	Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination	Preprint - Research Square	wrong outcome
Fisman et al.	Timing of Breakthrough Infection Risk After Vaccination Against SARS-CoV-2	Timing of Breakthrough Infection Risk After Vaccination Against SARS-CoV-2	wrong comparator
Fisman et al.	Timing of Breakthrough Infection Risk After Vaccination Against SARS-CoV-2	medRxiv	delayed exclusion - definition of unvaccinated group is unclear
Flacco et al.	Risk of SARS-CoV-2 reinfection 18 months after primary infection: population-level observational study	medRxiv	wrong study duration
Folegatti et al.	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial	Hand search; The Lancet	wrong outcome
Fontan et al.	Time-Varying Effectiveness of Three Covid-19 Vaccines in Puerto Rico	medRxiv	wrong outcome
Foulkes et al.	COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study	The Lancet	wrong intervention
Fournier et al.	SARS-CoV-2 Vaccination and Protection Against Clinical Disease: A Retrospective Study, Bouches-du-Rhône District, Southern France, 2021	Frontiers in Microbiology	delayed exclusion - baseline is <14 days, which is beyond our 30.5 days average post-receipt of second dose threshold.
Frenck et al.	Safety, immunogenicity, and efficacy of the BNT162B2 covid-19 vaccine in adolescents	New England Journal of Medicine	wrong intervention
Friedrichs et al.	Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort	Annals of the Rheumatic Diseases	wrong intervention
Fu et al.	POS-941 THE EFFECTIVENESS OF COVID-19 VACCINE IN REDUCING THE SEVERITY AND MORTALITY RATE AMONG THE END STAGE KIDNEY DISEASE WITH COVID-19	Kidney International Reports	Full-text not found

Fuca et al.	Antibody response to mRNA-1273 SARS-COV-2 vaccine in hemodialysis patients with and without prior COVID-19	Clinical Journal of the American Society of Nephrology	wrong intervention
Furer et al.	Immunogenicity and safety of the BNT162B2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and general population: A multicenter study	Annals of the Rheumatic Diseases	wrong intervention
Gaio et al.	COVID-19 vaccine effectiveness among healthcare workers in Portugal: results from a hospital-based cohort study, December 2020 to November 2021	medRxiv	wrong intervention
Garvey et al.	Early observations on the impact of a healthcare worker COVID-19 vaccination programme at a major UK tertiary centre	The Journal of Infection	wrong intervention
Gazit et al.	BNT162b2 mRNA Vaccine Effectiveness Given Confirmed Exposure: Analysis of Household Members of COVID-19 Patients	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America	wrong comparator
Gazit et al.	BNT162b2 mRNA Vaccine Effectiveness Given Confirmed Exposure; Analysis of Household Members of COVID-19 Patients	Preprint - medRxiv	wrong intervention
Gazit et al.	Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections	Preprint - medRxiv	wrong intervention
Geysels et al.	SARS-CoV-2 vaccine breakthrough infections among healthcare workers in a large Belgian hospital network	Infection Control and Hospital Epidemiology	wrong intervention
Ghadiri et al.	The study of COVID-19 infection following vaccination in patients with multiple sclerosis	Multiple sclerosis and related disorders	wrong outcome
Ghosh et al.	COVISHIELD (AZD1222) VaccINe effectiveness among healthcare and frontline Workers of INdian Armed Forces: Interim results of VIN-WIN cohort study	Medical Journal Armed Forces India	wrong intervention
Giansante et al.	COVID-19 vaccine effectiveness among the staff of the Bologna Health Trust, Italy, December 2020-April 2021	Acta Bio-medica: Atenei Parmensis	wrong intervention
Gilbert et al.	Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial	Preprint - medRxiv	wrong intervention
Glampson et al.	North West London Covid-19 Vaccination Programme: Real-world evidence for Vaccine uptake and effectiveness: Retrospective Cohort Study	JMIR Public Health and Surveillance	wrong intervention
Glatman-Freedman et al.	The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A nation-wide retrospective longitudinal multiple cohort analysis using individualised data	EBioMedicine	wrong study duration

Glatman-Freedman et al.	Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021	Emerging infectious diseases	wrong study duration
Goes et al.	New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil	Infection, Genetics and Evolution	wrong study design
Gohil et al.	Asymptomatic and Symptomatic COVID-19 Infections Among Health Care Personnel Before and After Vaccination	JAMA network open	wrong intervention
Goldberg et al.	Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel	Preprint - medRxiv	wrong intervention
Goldberg et al.	Waning Immunity after the BNT162b2 Vaccine in Israel	The New England journal of medicine	wrong comparator
Goldin et al.	BNT162b2 mRNA COVID-19 (Comirnaty) Vaccine Effectiveness in Elderly Patients Who Live in Long-Term Care Facilities: A Nationwide Cohort	Gerontology	wrong outcome
Goldshtein et al.	Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women	JAMA	wrong intervention
Gomes et al.	Is the BioNTech-Pfizer COVID-19 vaccination effective in elderly populations? Results from population data from Bavaria, Germany	Preprint - medRxiv	wrong intervention
Gomes et al.	Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany	PloS one	duplicated
Gounant et al.	Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses	Preprint - medRxiv	wrong intervention
Gower et al.	Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant	New England Journal of Medicine	duplicated
Gower et al.	Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study	The BMJ	duplicated
Gram et al.	Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study	PLoS medicine	wrong study duration
Gram et al.	Vaccine effectiveness when combining the ChAdOx1 vaccine as the first dose with an mRNA COVID-19 vaccine as the second dose	Preprint - medRxiv	wrong intervention

Grannis et al.	Interim estimates of COVID-19 vaccine effectiveness against COVID-19, associated emergency department or urgent care clinic encounters and hospitalizations among adults during SARS-CoV-2 B. 1.617. 2 (Delta) variant predominance, Nine States, June, August 2021	Morbidity and Mortality Weekly Report	wrong study duration
Grant et al.	Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France	The Lancet regional health. Europe	wrong study duration
Gray et al.	Vaccine effectiveness against hospital admission in South African health care workers who received a homologous booster of Ad26.COVID2 during an Omicron COVID19 wave: Preliminary Results of the Sisonke 2 Study	medRxiv	wrong intervention
Grima et al.	Relative Virulence of SARS-CoV-2 Among Vaccinated and Unvaccinated Individuals Hospitalized with SARS-CoV-2	medRxiv	wrong study duration
Guarino et al.	Effectiveness of SARS-Cov-2 vaccination in liver transplanted patients: the debate is open!	Journal of Hepatology	wrong outcome
Guha et al.	The incidence and in-hospital mortality of COVID-19 patients post-vaccination in eastern India	Preprint - medRxiv	wrong study design
Haas et al.	Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data	The Lancet	wrong intervention
Haas et al.	Infections, Hospitalizations, and Deaths Averted Via Direct Effects of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Vaccination Campaign, Israel	Preprint - SSRN	wrong intervention
Hall et al.	Effectiveness and durability of protection against future SARS-CoV-2 infection conferred by COVID-19 vaccination and previous infection; findings from the UK SIREN prospective cohort study of healthcare workers March 2020 to September 2021	medRxiv	delayed exclusion - a published version of this article is available
Hall et al.	Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients	New England Journal of Medicine	wrong comparator
Hammerman et al.	Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19	The New England journal of medicine	wrong intervention
Hansen et al.	Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or	medRxiv	delayed exclusion - last follow-up period is 91-150 days, which is insufficient to meet our 112-day lower limit.

	mRNA-1273 vaccination series: A Danish cohort study		
Hardt et al.	Efficacy and Safety of a Booster Regimen of Ad26.COVS Vaccine against Covid-19	medRxiv	wrong intervention
Harris et al.	Impact of vaccination on household transmission of SARS-COV-2 in England	Hand search; Preprint - medRxiv	wrong intervention
Havers et al.	COVID-19-associated hospitalizations among vaccinated and unvaccinated adults ≥18 years - COVID-NET, 13 states, January 1 - July 24, 2021	Preprint - medRxiv	wrong outcome
Herishanu et al.	Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia	Blood	wrong outcome
Herzberg et al.	SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study	Preprint - medRxiv	wrong intervention
Heudel et al.	Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients	Annals of Oncology	wrong intervention
Hitchings et al.	Effectiveness of the ChAdOx1 vaccine in the elderly during SARS-CoV-2 Gamma variant transmission in Brazil	Preprint - medRxiv	wrong intervention
Hitchings et al.	Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulation in Sao Paulo	Nature Communications	duplicate
Hoehl et al.	A new group at increased risk of a SARS-CoV-2 infection emerges: The recently vaccinated	Vaccine	wrong intervention
Hollinghurst et al.	COVID-19 Infection Risk amongst 14,104 Vaccinated Care Home Residents: A national observational longitudinal cohort study in Wales, United Kingdom, December 2020 to March 2021	Preprint - medRxiv	wrong intervention
Hoque et al.	Serial evaluation of anti-SARS-CoV-2 IgG antibody and breakthrough infections in BNT162b2 Vaccinated migrant workers from Bangladesh	medRxiv	wrong comparator
Horst	Covid-19 and Patients with IBD: Who Is at Highest Risk for Severe Complications?	Digestive Diseases and Sciences	wrong publication type
Hu et al.	Effectiveness of inactive COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant-infected patients in Jiangsu, China	Preprint - medRxiv	wrong intervention
Hulme et al.	Comparative effectiveness of ChAdOx1 versus BNT162b2 COVID-19 vaccines in Health and Social Care workers in England: a cohort study using OpenSAFELY	medRxiv	wrong intervention
Hung & Poland	Single-dose Oxford-AstraZeneca COVID-19 vaccine followed by a 12-week booster	The Lancet	wrong intervention
Hyams et al.	Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing	The Lancet Infectious Diseases	wrong intervention



	hospitalisations in people aged at least 80 years: a test-negative, case-control study		
Hyams et al.	Assessing the Effectiveness of BNT162b2 and ChAdOx1nCoV-19 COVID-19 Vaccination in Prevention of Hospitalisations in Elderly and Frail Adults: A Single Centre Test Negative Case-Control Study	Hand search; Preprint - SSRN	wrong intervention
Iliaki et al.	COVID-19 Vaccine Efficacy in a Diverse Urban Healthcare Worker Population	Preprint - medRxiv	wrong intervention
Ioannou et al.	COVID-19 Vaccination Effectiveness Against Infection or Death in a National U.S. Health Care System : A Target Trial Emulation Study	Annals of internal medicine	wrong study duration
Irizarry et al.	Time-Varying Effectiveness of Three Covid-19 Vaccines in Puerto Rico	SSRN	delayed exclusion - study ID 18-3 is a more recent version of this study
Iskander et al.	Effectiveness of vaccination against reported SARS-CoV-2 infection in United States Coast Guard personnel between May and August 2021: A time-series analysis	medRxiv	wrong comparator
Ismail et al.	Effectiveness of BNT162b2 mRNA and ChAdOx1 adenovirus vector COVID-19 vaccines on risk of hospitalisation among older adults in England: an observational study using surveillance data	Hand search - Public Health England preprint	wrong intervention
Israel et al.	Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection	Preprint - medRxiv	wrong outcome
Israel, et al.	Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort	medRxiv	delayed exclusion - study included only vaccinated individuals. The authors presented risk of COVID infection according to the time since the vaccination (greater or lower than 146 days) in Table 3 (but no indication of individual level follow-up time).
Issac et al.	SARS-CoV-2 Breakthrough Infections among the Healthcare Workers Post-Vaccination with ChAdOx1 nCoV-19 Vaccine in the South Indian State of Kerala	Preprint - medRxiv	wrong intervention
Italian Istituto Superiore di Sanita	Impact of COVID-19 vaccination on the risk of SARS-CoV-2 infection and hospitalization and death in Italy	Report forwarded by PHAC	wrong comparator
Jablonska et al.	The real-life impact of vaccination on COVID-19 mortality in Europe and Israel	Preprint - medRxiv	wrong population
Jacobson et al.	Post-vaccination SARS-CoV-2 infections and incidence of presumptive B.1.427/B.1.429 variant among healthcare personnel at a northern California academic medical center	Clinical Infectious Diseases	wrong intervention

Jacobson et al.	Post-vaccination SARS-CoV-2 infections and incidence of the B.1.427/B.1.429 variant among healthcare personnel at a northern California academic medical center	Preprint - medRxiv	uplicated
Jacquemont et al.	Minimal change disease relapse following SARS-CoV-2 mRNA vaccine	Kidney International	wrong study design
Jagadeesh Kumar et al.	Clinical outcomes in vaccinated individuals hospitalized with Delta variant of SARS-CoV-2	Preprint - medRxiv	wrong intervention
Jalali et al.	Increased household transmission and immune escape of the SARS-CoV-2 Omicron variant compared to the Delta variant: evidence from Norwegian contact tracing and vaccination data	medRxiv	wrong study duration
Jara et al.	Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile	Hand search; New England Journal of Medicine	wrong intervention
Jeulin et al.	Comparative analysis of post-vaccination anti-spike IgG antibodies in old Nursing Home Residents and in middle-aged Healthcare workers	Preprint - medRxiv	wrong outcome
June Choe et al.	Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents	Vaccine	wrong population
Kale et al.	Clinicogenomic analysis of breakthrough infections by SARS CoV2 variants after ChAdOx1 nCoV-19 vaccination in healthcare workers	Hand search; Preprint - medRxiv	wrong intervention
Kamar et al.	Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients	The New England Journal of Medicine	wrong intervention
Kannian et al.	Booster and anergic effects of the Covishield vaccine among healthcare workers in South India	Preprint - medRxiv	wrong outcome
Katz et al.	Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI)	Vaccine	wrong outcome
Katz et al.	Covid-19 Vaccine Effectiveness in Healthcare Personnel in six Israeli Hospitals (CoVEHPI)	Preprint - medRxiv	wrong intervention
Kaur et al.	Occurrence of COVID-19 in priority groups receiving ChAdOx1 nCoV-19 coronavirus vaccine (recombinant): a preliminary analysis from north India	Journal of Medical Virology	wrong intervention
Keegan et al.	Progress of the Delta variant and erosion of vaccine effectiveness, a warning from Utah	Preprint - medRxiv	wrong study design
Keehner et al.	SARS-CoV-2 Infection after Vaccination in Health Care Workers in California	The New England Journal of Medicine	wrong intervention
Keehner et al.	Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce.	The New England Journal of Medicine	delayed exclusion - a series of cross-sectional analysis over months (no indication of individual level follow-up times)

Keeling et al.	Waning, boosting and a path to endemicity for SARS-CoV-2	medRxiv	wrong population
Kepten et al.	BNT162B2 mRNA covid-19 vaccine in a nationwide mass vaccination setting	New England Journal of Medicine	duplicated
Kertes et al.	Effectiveness of the mRNA BNT162b2 vaccine six months after vaccination: Findings from a large Israeli HMO.	Hand search; Preprint - medRxiv	wrong control
Khan & Mahmud	Effectiveness of SARS-CoV-2 vaccination in a Veterans Affairs Cohort of Inflammatory Bowel Disease Patients with Diverse Exposure to Immunosuppressive Medications	Gastroenterology	wrong study duration
Khan et al.	SAFETY AND EFFECTIVENESS OF THE BNT162B2 MRNA COVID-19 VACCINE IN A NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE	Gastroenterology	Full text unavailable
Khan et al.	Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications	Gastroenterology	wrong intervention
Khoury et al.	COVID-19 vaccine - Long term immune decline and breakthrough infections	Vaccine	wrong comparator
Kim et al.	mRNA Vaccine Effectiveness against COVID-19 among Symptomatic Outpatients Aged ≥16 Years in the United States, February - May 2021	The Journal of Infectious Diseases	wrong intervention
Kim et al.	mRNA Vaccine Effectiveness against COVID-19 among Symptomatic Outpatients Aged ≥16 Years in the United States, February - May 2021	The Journal of infectious diseases	wrong comparator
Kislaya et al.	Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants	medRxiv	wrong comparator
Kislaya et al.	Comparative Effectiveness of Coronavirus Vaccine in Preventing Breakthrough Infections among Vaccinated Persons Infected with Delta and Alpha Variants	Emerging infectious diseases	wrong study duration
Kislaya et al.	Delta variant and mRNA Covid-19 vaccines effectiveness: higher odds of vaccine infection breakthroughs	Preprint - medRxiv	wrong intervention
Kissling et al.	Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021	Hand search; Eurosurveillance	wrong intervention
Klaassen et al.	Population immunity to pre-Omicron and Omicron SARS-CoV-2 variants in US states and counties through December 1, 2021	medRxiv	wrong intervention

Klaser et al.	COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: two prospective observational cohort studies	medRxiv	wrong study duration
Knobel et al.	Coronavirus disease 2019 (COVID-19) mRNA vaccine effectiveness in asymptomatic healthcare workers	Infection Control and Hospital Epidemiology	wrong intervention
Knobel et al.	COVID-19 mRNA vaccine effectiveness in asymptomatic healthcare workers	Infection Control and Hospital Epidemiology	wrong intervention
Knoll et al.	Oxford-AstraZeneca COVID-19 vaccine efficacy	The Lancet	wrong publication type
Kontou et al.	Antibody response following a two-dose mRNA vaccination regimen, in health care workers of a tertiary hospital in Athens, Greece	Journal of Personalized Medicine	wrong intervention
Koshy	Effectiveness of ChAdOx1 nCoV-19 Vaccine: Experience of a tertiary care institute	Medical Journal Armed Forces India	wrong outcome
Krisztina et al.	Real-time monitoring of the effectiveness of six COVID-19 vaccines in Hungary in 2021 using the screening method	medRxiv	wrong intervention
Kugeler et al.	Estimating the number of symptomatic SARS-CoV-2 infections among vaccinated individuals in the United State - January-April, 2021	Preprint - medRxiv	wrong study design
Kustin et al.	Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals	Preprint - medRxiv	wrong study design
Lamacchia et al.	Clinical and immunological features of SARS-CoV-2 breakthrough infections in vaccinated individuals requiring hospitalization	medRxiv	wrong outcome
Landre et al.	1600P Suboptimal response to COVID-19 mRNA vaccines in older patients with cancer	Annals of Oncology	wrong comparator
Lange et al.	Immune response to COVID-19 mRNA vaccine-a pilot study	Vaccines	wrong intervention
Lanini et al.	A single intramuscular injection of monoclonal antibody MAD0004J08 induces in healthy adults SARS-CoV-2 neutralising antibody titres exceeding those induced by infection and vaccination	Preprint - medRxiv	wrong intervention
Lanthier et al.	[In subjects 16 years of age and older, is messenger RNA vaccine BNT162b2 against COVID-19 effective and safe?]	La Revue de Médecine Interne	wrong intervention
Larese Filon et al.	Incidence of COVID-19 infection in hospital workers from March 1, 2020 to May 31, 2021 routinely tested, before and after vaccination with BNT162B2	Scientific reports	wrong study duration
Lauring et al.	Clinical Severity and mRNA Vaccine Effectiveness for Omicron, Delta, and Alpha	medRxiv	wrong comparator

	SARS-CoV-2 Variants in the United States: A Prospective Observational Study		
Layan et al.	Impact of BNT162b2 vaccination and isolation on SARS-CoV-2 transmission in Israeli households: an observational study	Preprint - medRxiv	wrong intervention
Lee et al.	POS-950 COVID-19 IN END STAGE KIDNEY DISEASE WITH RENAL REPLACEMENT THERAPIES: OUR EXPERIENCE IN PENANG	Kidney International Reports	Full-text not found
Lefèvre et al.	Beta SARS-CoV-2 variant and BNT162b2 vaccine effectiveness in long-term care facilities in France	The Lancet. Healthy longevity	wrong study duration
Lefèvre et al.	Impact of B. 1.351 (beta) SARS-CoV-2 variant on BNT162b2 mRNA vaccine effectiveness in long-term care facilities of eastern France: a retrospective cohort study	medRxiv	uplicated
Leo	Effectiveness of the mRNA BNT162b2 vaccine against SARS-CoV-2 severe infections in the Israeli over 60 population: a temporal analysis done by using the national surveillance data	medRxiv	wrong study duration
Lev-Tzion et al.	COVID-19 vaccine is effective in inflammatory bowel disease patients and is not associated with disease exacerbation	Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association	wrong outcome
Lewis et al.	Effectiveness of mRNA vaccines in preventing COVID-19 hospitalization by age and burden of chronic medical conditions among immunocompetent US adults, March-August 2021	The Journal of infectious diseases	wrong study duration
Lillie et al.	First dose of BNT162b2 mRNA vaccine in a Health Care Worker cohort is associated with reduced symptomatic and asymptomatic SARS-CoV-2 infection	Clinical Infectious Diseases	wrong intervention
Lim et al.	POS-962 A SURVEY OF COVID-19 INFECTION AMONG VACCINATED AND UNVACCINATED PATIENTS ON RENAL REPLACEMENT THERAPY: A SINGLE CENTRE EXPERIENCE	Kidney International Reports	Full-text not found
Lin et al.	Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina	The New England journal of medicine	wrong intervention
Lippi & Mattiuzzi	Primary COVID-19 vaccine cycle and booster doses efficacy: analysis of Italian nationwide vaccination campaign	European journal of public health	delayed exclusion - baseline is < 6 month, which is beyond our 30.5 days average post-receipt of second dose threshold
Lippi et al.	Real-world analysis of age-dependent efficacy of COVID-19 vaccination	Research Square	wrong comparator
Liu et al.	A Retrospective Analysis of COVID-19 mRNA Vaccine Breakthrough Infections ,Risk Factors and Vaccine Effectiveness	medRxiv	delayed exclusion - no comparative data for unvaccinated individuals

Lo Sasso et al.	Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine	Diagnostics (Basel, Switzerland)	wrong outcome
Lopez Bernal et al.	Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant	The New England Journal of Medicine	duplicated
Lopez Bernal et al.	Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study	BMJ (Clinical Research Ed.)	wrong intervention
Lumley et al.	An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status	Preprint - medRxiv	duplicated
Lumley et al.	An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status	Clinical Infectious Diseases	wrong intervention
Ma et al.	Effectiveness of Covid-19 Vaccines against the SARS-COV-2-Delta (B.1.617.2) in China-A Real World Study	medRxiv	wrong outcome
Madhi et al.	ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant. Reply	The New England Journal of Medicine	wrong publication type
Madhi et al.	Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa	Preprint - medRxiv	duplicated
Maeda et al.	Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the Delta variant epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)	medRxiv	wrong comparator
Mahase	Covid-19: Pfizer vaccine's efficacy declined from 96% to 84% four months after second dose, company reports	BMJ (Clinical Research Ed.)	wrong publication type
Mallow et al.	Real world SARS-COV-2 vaccine effectiveness in a Miami academic institution	The American journal of emergency medicine	wrong study duration
Maltezou et al.	COVID-19 vaccination significantly reduces morbidity and absenteeism among healthcare personnel: A prospective multicenter study	Vaccine	wrong study duration
Maneikis et al.	Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study	The Lancet Haematology	wrong intervention
Manley et al.	SARS-CoV-2 vaccine effectiveness and breakthrough infections in maintenance dialysis patients	medRxiv	wrong outcome
Manley et al.	SARS-CoV-2 vaccine effectiveness and breakthrough infections in maintenance dialysis patients	medRxiv	wrong study duration

Martinez-Baz et al.	Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021	Eurosurveillance	wrong intervention
Martínez-Baz et al.	Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021	Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin	wrong comparator
Martinot et al.	Outbreak of SARS-CoV-2 infection in a long-term care facility after COVID-19 BNT162b2 mRNA vaccination	Clinical Microbiology and Infection	wrong intervention
Massimo et al.	COVID-19 convalescent plasma donors: impact of vaccination on antibody levels, breakthrough infections and reinfection rate	Preprint - medRxiv	wrong intervention
Massonnaud et al.	Evaluating COVID-19 booster vaccination strategies in a partially vaccinated population: a modeling study	SSRN	wrong study design
Mateo-Urdiales et al.	Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021	Hand search; Eurosurveillance	wrong intervention
Mateus et al.	Low dose mRNA-1273 COVID-19 vaccine generates durable T cell memory and antibodies enhanced by pre-existing crossreactive T cell memory	Preprint - medRxiv	wrong outcome
Mathema et al.	Post-vaccination SARS-COV-2 among healthcare workers in New Jersey: a genomic epidemiological study	Preprint - medRxiv	wrong intervention
Mattar et al.	Efficacy of the CoronaVac® Vaccine in a Region of the Colombian Amazon, Was Herd Immunity Achieved?	Preprint - Research Square	wrong intervention
Mattiuzzi & Lippi	Primary COVID-19 vaccine cycle and booster doses efficacy: analysis of Italian nationwide vaccination campaign	European journal of public health	wrong comparator
Mattiuzzi & Lippi	Efficacy of COVID-19 vaccine booster doses in older people	European geriatric medicine	wrong comparator
Mattiuzzi & Lippi	<p>COVID-19 vaccination is highly effective to prevent SARS-CoV-2 circulation</p>	Research Square	wrong comparator
Mazagatos et al.	Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021	Eurosurveillance	wrong intervention
McConaghy et al.	An assessment of the impact of the vaccination program on coronavirus disease 2019 (COVID-19) outbreaks in care homes in Northern Ireland-A pilot study	Infection Control and Hospital Epidemiology	wrong intervention

McConeghy et al.	Effectiveness of a SARS-CoV-2 mRNA vaccine booster dose for prevention of infection, hospitalization or death in two nation-wide nursing home systems	medRxiv	wrong outcome
McDade et al.	Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history	Scientific Reports	wrong intervention
McEllistrem et al.	Introduction of the BNT162b2 vaccine during a COVID-19 nursing home outbreak	American Journal of Infection Control	wrong intervention
McEvoy et al.	Real-world Effectiveness of 2-dose SARS-CoV-2 Vaccination in Kidney Transplant Recipients	medRxiv	wrong comparator
McKeigue et al.	Efficacy of vaccination against severe COVID-19 in relation to Delta variant and time since second dose: the REACT-SCOT case-control study	medRxiv	wrong comparator
McKeon et al.	Real-world effectiveness and immunogenicity of mRNA-1273 in dialysis patients	Journal of the American Society of Nephrology	wrong intervention
McLean et al.	mRNA COVID-19 vaccine effectiveness against SARS-CoV-2 infection in a prospective community cohort, rural Wisconsin, November 2020-December 2021	medRxiv	wrong outcome
McLean et al.	mRNA COVID-19 vaccine effectiveness against SARS-CoV-2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021	Influenza and other respiratory viruses	wrong study duration
Medeiros et al.	Reduced T cell and antibody responses to inactivated coronavirus vaccine among males and individuals above 55 years old	Preprint - medRxiv	wrong intervention
Medina-Pestana et al.	Inactivated Whole-virus Vaccine Triggers Low Response Against SARS-CoV-2 Infection Among Renal Transplant Patients: Prospective Phase 4 Study Results	Transplantation	wrong intervention
Meggiolaro et al.	Effectiveness of vaccination against symptomatic and asymptomatic SARS-CoV-2 infection: a systematic review and meta-analysis	Preprint - medRxiv	wrong study design
Mehta & Silveira	COVID-19 after two doses of mRNA vaccines in kidney transplant recipients	American Journal of Transplantation	wrong intervention
Menascu et al.	Safety and efficacy of COVID-19 Pfizer-BNT162b2 m-RNA vaccine in young MS population	Multiple Sclerosis Journal	wrong comparator
Menni et al.	Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study	The Lancet Infectious Diseases	wrong intervention
Meo et al.	Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world	European review for medical and pharmacological sciences	wrong outcome



	settings at countrywide vaccination campaign in Saudi Arabia		
Meo et al.	COVID-19 vaccines: Comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna vaccines	European Review for Medical and Pharmacological Sciences	wrong study design
Meylan	Efficacy and safety of BioNTech/Pfizer and Moderna vaccines	Revue Medicale Suisse	wrong publication type
Meylan	Safety and efficacy of the Oxford-AstraZeneca vaccine: Interim analysis of four randomized controlled trials	Revue Medicale Suisse	wrong intervention
Michos et al.	Association of total and neutralizing SARS-CoV-2 spike -receptor binding domain antibodies with epidemiological and clinical characteristics after immunization with the 1st and 2nd doses of the BNT162b2 vaccine	Vaccine	wrong outcome
Mielke et al.	Fully Vaccinated and Boosted Patients Requiring Hospitalization for COVID-19: an Observational Cohort Analysis	medRxiv	wrong outcome
Mirahmadizadeh et al.	Effectiveness of COVID-19 Vaccines in preventing Infectiousness, Hospitalization and Mortality: A Historical Cohort Study Using Iranian Registration Data During Vaccination program	medRxiv	wrong study duration
Miron et al.	Effectiveness of COVID-19 Vaccines BNT162b2 and mRNA-1273 by Days from Vaccination: A Reanalysis of Clinical Trial Data	Preprint - SSRN	wrong intervention
Mittelman et al.	Effectiveness of the BNT162b2 mRNA Covid-19 Vaccine in Patients with Hematological Neoplasms	Blood	wrong study duration
Mizrahi et al.	Correlation of SARS-CoV-2 Breakthrough Infections to Time-from-vaccine; Preliminary Study	Preprint - medRxiv	wrong outcome
Mizrahi et al.	Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine	Nature Communications	duplicated
Molani et al.	Time to reinfection and vaccine breakthrough SARS-CoV-2 infections: a retrospective cohort study	medRxiv	wrong outcome
Moline et al.	Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged $\geq 65$ Years - COVID-NET, 13 States, February-April 2021	Morbidity and Mortality Weekly Report	wrong intervention
Moncunill et al.	Determinants of early antibody responses to COVID-19 mRNA vaccines in exposed and naive healthcare workers	medRxiv	wrong study duration
Monge et al.	Direct and Indirect Effectiveness of mRNA Vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 in Long-Term Care Facilities, Spain	Emerging Infectious Diseases	wrong intervention

Monge et al.	Direct and Indirect Effectiveness of mRNA Vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 in Long-Term Care Facilities, Spain	Emerging infectious diseases	wrong study duration
Mor et al.	BNT162b2 Vaccination efficacy is marginally affected by the SARS-CoV-2 B.1.351 variant in fully vaccinated individuals	Preprint - medRxiv	wrong population
Mor et al.	BNT162b2 vaccine effectiveness was marginally affected by the $\gamma$ SARS-CoV-2 $\beta$ variant in fully vaccinated individuals	Journal of clinical epidemiology	uplicated
Moustsen Helms et al.	Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term care facility residents and healthcare workers—a Danish cohort study	Preprint - medRxiv	wrong intervention
Muhsen et al.	Effectiveness of BNT162b2 mRNA COVID-19 vaccine against acquisitions of SARS-CoV-2 among health care workers in long-term care facilities: a prospective cohort study	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America	wrong study duration
Muhsen et al.	Effectiveness of BNT162b2 mRNA COVID-19 vaccine against acquisitions of SARS-CoV-2 among health care workers in long-term care facilities: a prospective cohort study	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America	wrong study duration
Munitz et al.	BNT162b2 vaccination effectively prevents the rapid rise of SARS-CoV-2 variant B.1.1.7 in high-risk populations in Israel	Cell Reports Medicine	wrong intervention
Murillo-Zamora et al.	Effectiveness of BNT162b2 COVID-19 Vaccine in Preventing Severe Symptomatic Infection among Healthcare Workers	Medicina (Kaunas, Lithuania)	wrong intervention
Murt et al.	Antibody responses to the SARS-CoV-2 vaccines in hemodialysis patients: Is inactivated vaccine effective?	Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy	wrong comparator
Musser et al.	Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas	Preprint - medRxiv	wrong study design
Naaber et al.	Declined antibody responses to COVID-19 mRNA vaccine within first three months	Preprint - medRxiv	wrong outcome
Naito et al.	Real-world evidence for the effectiveness and breakthrough of BNT162b2 mRNA COVID-19 vaccine at a medical center in Japan	Human vaccines & immunotherapeutics	wrong outcome
Naleway et al.	Incidence of SARS-CoV-2 Infection, Emergency Department Visits, and Hospitalizations Because of COVID-19 Among	MMWR. Morbidity and mortality weekly report	wrong study duration

	Persons Aged ≥12 Years, by COVID-19 Vaccination Status - Oregon and Washington, July 4-September 25, 2021		
Nanduri et al.	Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021	Morbidity and Mortality Weekly Report	wrong study design
Naranbhai et al.	Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines	medRxiv	wrong population
Nasreen et al.	Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario	Nature microbiology	wrong study duration
Nasreen et al.	Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada	Preprint - medRxiv	wrong intervention
Nasreen et al.	Effectiveness of COVID-19 vaccines against variants of concern, Canada	Hand search; Preprint - medRxiv	wrong intervention
Nasreen et al.	Effectiveness of mRNA and ChAdOx1 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario	medRxiv	wrong study duration
Nguyen et al.	Comparative effectiveness of ChAdOx1 versus BNT162b2 vaccines against SARS-CoV-2 infections in England and Wales: A cohort analysis using trial emulation in the Virus Watch community data	medRxiv	wrong comparator
Nomura et al.	Age and smoking predict antibody titres at 3 months after the second dose of the BNT162b2 COVID-19 vaccine	Preprint - medRxiv	wrong outcome
Nordström et al.	Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study	The Lancet regional health. Europe	wrong study duration
Nunes et al.	mRNA vaccines effectiveness against COVID-19 hospitalizations and deaths in older adults: a cohort study based on data-linkage of national health registries in Portugal	Preprint - medRxiv	wrong intervention
Nunes et al.	mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: a cohort study based on data linkage of national health registries in Portugal, February to August 2021	Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin	wrong study duration
Nunez Lopez et al.	Effectiveness of the BNT162b2 mRNA Covid-19 vaccine in Spanish healthcare workers	Enfermedades Infecciosas y Microbiología Clínica	wrong intervention

Olson et al.	Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12-18 Years - United States, June-September 2021	MMWR. Morbidity and mortality weekly report	wrong study duration
Oster et al.	Association Between Exposure Characteristics and the Risk for COVID-19 Infection Among Health Care Workers With and Without BNT162b2 Vaccination	JAMA network open	wrong study design
Ostropolets & Hripcsak	COVID-19 vaccination effectiveness rates by week and sources of bias	medRxiv	delayed exclusion - VE for full vaccination is not stratified by time since full vaccination (see appendix 7-9). As for VE that is stratified by time (Figure 3 and 4), time is calculated from receipt of first dose, not second. There are no week-by-week estimates for single-dose Janssen because of the small sample size
Paetzold et al.	The effects of rapid mass vaccination against SARS-CoV-2 and its Variants-of-Concern: Evidence from an early VoCs hotspot	Preprint – Research Square	wrong study design
Painter et al.	Rapid induction of antigen-specific CD4+ T cells guides coordinated humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination	Preprint - bioRxiv	wrong outcome
Pajon et al.	Initial Analysis of Viral Dynamics and Circulating Viral Variants During the mRNA-1273 Phase 3 COVE Trial	medRxiv	wrong study duration
Palich et al.	Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients	Annals of Oncology	wrong outcome
Palladino et al.	A quantitative risk-benefit analysis of ChAdOx1 nCoV-19 vaccine among people under 60 in Italy	Preprint - medRxiv	wrong study design
Panasoff et al.	Specific antibody response of patients with common variable immunodeficiency to BNT162b2 coronavirus disease 2019 vaccination	Annals of Allergy, Asthma and Immunology	wrong outcome
Papousek et al.	Experience with the production of COVID-19 convalescent plasma in a tertiary hospital	Vox Sanguinis	wrong outcome
Paris et al.	Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data	Clinical Microbiology and Infection	wrong intervention
Parry et al.	Extended interval BNT162b2 vaccination enhances peak antibody generation in older people	Preprint - medRxiv	wrong outcome

Parry et al.	Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia	Blood Cancer Journal	wrong outcome
Parry et al.	Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia	Blood cancer Journal	wrong outcome
Pascucci et al.	Evaluation of the Effectiveness and Safety of the BNT162b2 COVID-19 Vaccine in the Vaccination Campaign among the Health Workers of Fondazione Policlinico Universitario Agostino Gemelli IRCCS	International journal of environmental research and public health	wrong study duration
Passalacqua et al.	Efficacy of SARS-CoV-2 vaccination in cancer patients during treatment: A prospective observational study (ANTICOV trial)	Tumori	wrong study duration
Pattni et al.	Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2	medRxiv	wrong outcome
Paulsen et al.	Immune Thrombocytopenic Purpura after vaccination with COVID-19 Vaccine (ChAdOx1 nCov-19)	Blood	wrong study design
Pawlowski et al.	FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system	Med (New York, N.Y.)	wrong intervention
Payne et al.	Sustained T cell immunity, protection and boosting using extended dosing intervals of BNT162b2 mRNA vaccine	Hand search; Preprint - SSRN	wrong outcome
Peet et al.	COVID-19 infection and vaccination in patients with autoinflammatory diseases on biologics	Pediatric Rheumatology	wrong outcome
Pefaur Penna et al.	POS-912 EFFECTIVENESS OF SARS-COV 2 VACCINATION IN KIDNEY TRANSPLANT PATIENTS IN CHILE	Kidney International Reports	Full-text not found
Pegu et al.	Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants	Science (New York, N.Y.)	wrong outcome
Peled et al.	BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response	Journal of Heart and Lung Transplantation	wrong intervention
Perkmann et al.	Serum antibody response to BNT162b2 after natural SARS-CoV-2 infection	European Journal of Clinical Investigation	wrong outcome
Pilishvili et al.	Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel - 33 U.S. Sites, January-March 2021	Morbidity and Mortality Weekly Report	wrong intervention
Polinski et al.	Effectiveness of the Single-Dose Ad26.COVS.2 COVID Vaccine	medRxiv	wrong outcome

Porru et al.	Post-Vaccination SARS-CoV-2 Infections among Health Workers at the University Hospital of Verona, Italy: A Retrospective Cohort Survey	Vaccines	wrong outcome
Pouwels et al.	Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK	Preprint - medRxiv	wrong intervention
Pouwels et al.	Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK	Nature medicine	uplicated
Pozdnyakova et al.	Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients with Inflammatory Bowel Disease	Gastroenterology	wrong outcome
Pozzetto et al.	Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination	Preprint - Research Square	wrong intervention
Prabhu et al.	Antibody Response to Coronavirus Disease 2019 (COVID-19) Messenger RNA Vaccination in Pregnant Women and Transplacental Passage Into Cord Blood	Obstetrics and Gynecology	wrong intervention
Pramod et al.	Effectiveness of Covishield vaccine in preventing Covid-19 - A test-negative case-control study	Vaccine	wrong study duration
Prasad et al.	COVID-19 Vaccination Associated with Reduced Post-Operative SARS-CoV-2 Infection and Morbidity	Annals of Surgery	wrong intervention
Pratesi et al.	BNT162b2 mRNA SARS-CoV-2 vaccine elicits high avidity and neutralizing antibodies in healthcare workers	Vaccines	wrong outcome
Pratò et al.	SARS-CoV-2 Transmission Risk to Household and Family Contacts by Vaccinated Healthcare Workers	Journal of Occupational and Environmental Medicine	wrong intervention
Prendecki et al.	Comparison of humoral and cellular responses in kidney transplant recipients receiving BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines	Preprint - medRxiv	wrong outcome
Prendecki et al.	Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression	Annals of the Rheumatic Diseases	wrong outcome
Prieto Alhambra et al.	Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2: a cohort analysis	Research Square	wrong comparator
Pritchard et al.	Impact of vaccination on new SARS-CoV-2 infections in the UK	Nature Medicine	wrong intervention
Prunas et al.	Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents	medRxiv	wrong population

Prunas et al.	Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel	Preprint - medRxiv	wrong study design
Puranik et al.	Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection	Med (New York, N.Y.)	wrong comparator
Puranik et al.	Comparison of Two Highly-Effective mRNA Vaccines for COVID-19 During Periods of Alpha and Delta Variant Prevalence	Preprint - medRxiv	uplicated
Puranik et al.	Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence	medRxiv	delayed exclusion - retrospective cohort study (matched unvaccinated and vaccinated individuals). The authors present Kaplan-Meier plots with VE data, but no extractable information (Figure 2 and Figure S2). Additional VE by month data presented in the Table 3 for Breakthrough infections, that comes from modelling (but no indication of the individual level follow-up time across the specified time period)
Ramirez et al.	Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'	Annals of the Rheumatic Diseases	wrong outcome
Ramirez et al.	SARS-CoV-2 Breakthrough Infections in Fully Vaccinated Individuals	Preprint - medRxiv	wrong outcome
Ranzani et al.	Vaccine effectiveness of ChAdOx1 nCoV-19 against COVID-19 in a socially vulnerable community in Rio de Janeiro, Brazil: a test-negative design study	Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases	wrong study duration
Redjoul et al.	Antibody response after second BNT162b2 dose in allogeneic HSCT recipients	The Lancet	wrong outcome
Redmond et al.	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in vaccinated and unvaccinated healthcare personnel in a Veterans' Affairs healthcare system	Infection Control and Hospital Epidemiology	wrong intervention
Regev Yochay et al.	4th Dose COVID mRNA Vaccines,Â Immunogenicity & Efficacy Against Omicron VOC	medRxiv	wrong comparator
Revon-Riviere et al.	The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience	European Journal of Cancer	wrong intervention

Revon-Riviere et al.	The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience	European Journal of Cancer	wrong study duration
Risk et al.	Comparative Effectiveness of COVID-19 Vaccines against the Delta Variant	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America	wrong comparator
Roberts et al.	Estimating COVID-19 Vaccination Effectiveness Using Electronic Health Records of an Academic Medical Center in Michigan	medRxiv	wrong comparator
Robilotti et al.	Clinical and Genomic Characterization of SARS CoV-2 infections in mRNA Vaccinated Health Care Personnel in New York City	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America	wrong study duration
Rodríguez-Espinosa et al.	Incidence of severe breakthrough SARS-CoV-2 infections in vaccinated kidney transplant and haemodialysis patients	Journal of nephrology	wrong comparator
Roest et al.	BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting	New England Journal of Medicine	uplicated
Rosenberg et al.	New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3– July 25, 2021	Hand search; Morbidity and Mortality Weekly Report	wrong intervention
Rosenberg et al.	COVID-19 Vaccine Effectiveness by Product and Timing in New York State	medRxiv	wrong outcome
Rosero Bixby	Vaccine effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca to prevent severe COVID-19 in Costa Rica by September and October 2021: A nationwide, observational study of hospitalisations prevalence	Europe PMC	wrong study duration
Rosero-Bixby	Vaccine effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca to prevent severe COVID-19 in Costa Rica by September and October 2021: A nationwide, observational study of hospitalisations prevalence	medRxiv	wrong study duration
Rovida et al.	SARS-CoV-2 vaccine breakthrough infections are asymptomatic or mildly symptomatic and are infrequently transmitted	medRxiv	delayed exclusion - not enough time of follow up (4 months criterion)
Russo et al.	SARS-COV-2 vaccination with BNT162B2 in renal transplant patients: Risk factors for impaired response and immunological implications	Clinical Transplantation	wrong outcome
Saban et al.	Changes in infectivity, severity and vaccine effectiveness against delta COVID-19 variant ten months into the vaccination program: The Israeli case	Preventive medicine	wrong intervention



Sabnis et al.	Break-through COVID-19 infection rate with Indian strain in Single-center Healthcare Workers: A real world data	Preprint - medRxiv	wrong outcome
Saciuk et al.	Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel	Preventive medicine	wrong study duration
Saciuk et al.	Pfizer-BioNTech Vaccine Effectiveness Against SARS-CoV-2 Infection: Findings From a Large Observational Study in Israel	Hand search; Preprint - SSRN	duplicated
Saciuk et al.	Pfizer-BioNTech Vaccine Effectiveness Against SARS-CoV-2 Infection: Findings From a Large Observational Study in Israel	Preprint - SSRN	wrong intervention
Saciuk et al.	Effectiveness of a third dose of BNT162b2 mRNA vaccine	The Journal of infectious diseases	wrong comparator
Sacks	The single-dose J&J vaccine had 67% efficacy against moderate to severe-critical COVID-19 at >=14 d	Annals of Internal Medicine	wrong publication type
Sadoff et al.	Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19	The New England Journal of Medicine	delayed exclusion - data is in graphs and not easily extractable at this point in time
Sagiraju et al.	The effectiveness of SARS-CoV-2 vaccination in preventing severe illness and death—real-world data from a cohort of patients hospitalized with COVID-19	Preprint - medRxiv	wrong intervention
Sansone et al.	Effectiveness of BNT162b2 vaccine against SARS-CoV-2 among healthcare workers	La Medicina del Lavoro	wrong intervention
Sarkar et al.	Seroprevalence and Dynamics of anti-SARS-CoV-2 antibody among healthcare workers following ChAdOx1 nCoV-19 vaccination	Preprint - medRxiv	wrong intervention
Saul et al.	Reanalysis of the Pfizer mRNA BNT162b2 SARS-CoV-2 vaccine data fails to find any increased efficacy following the boost: Implications for vaccination policy and our understanding of the mode of action	Preprint - medRxiv	wrong intervention
Saure et al.	Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study	The Lancet Infectious Diseases	wrong outcome
Scobie et al.	Monitoring incidence of covid-19 cases, hospitalizations, and deaths, by vaccination status, 13 US jurisdictions, April 4, 2021	Morbidity and Mortality Weekly Report	wrong comparator
Selby et al.	Effect of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) mRNA vaccination in healthcare workers with high-risk coronavirus disease 2019 (COVID-19) exposure	Infection Control and Hospital Epidemiology	wrong intervention
Self et al.	Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without	MMWR. Morbidity and mortality weekly report	wrong comparator

	Immunocompromising Conditions - United States, March-August 2021		
Shah et al.	Effect of vaccination on transmission of COVID-19: an observational study in healthcare workers and their households	Preprint - medRxiv	wrong intervention
Shapiro et al.	Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer	Cancer cell	wrong comparator
Sharma et al.	Effectiveness of a third dose of BNT162b2 or mRNA-1273 vaccine for preventing post-vaccination COVID-19 infection: an observational study	medRxiv	wrong outcome
Sharma et al.	COVID-19 Vaccine Breakthrough Infections in Veterans Health Administration	medRxiv	wrong comparator
Sheikh et al.	BNT162b2 and ChAdOx1 nCoV-19 vaccine effectiveness against death from the delta variant	New England Journal of Medicine	wrong study duration
Sheikh et al.	SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness	The Lancet	wrong intervention
Shinde et al.	Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant	Hand search; New England Journal of Medicine	wrong intervention
Shostak et al.	Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine	The Lancet Respiratory Medicine	wrong intervention
Shrestha et al.	Coronavirus Disease 2019 (COVID-19) Vaccine Boosting in Persons Already Protected by Natural or Vaccine-Induced Immunity	medRxiv	wrong comparator
Shrestha et al.	Necessity of COVID-19 vaccination in previously infected individuals	medRxiv	delayed exclusion - a retrospective cohort study that estimated cumulative incidence of COVID infection over five months, among previously infected subjects who received the vaccine, compared with those of previously infected subjects who remained unvaccinated, previously uninfected subjects who received the vaccine, and previously uninfected subjects who remained unvaccinated. Figure 3 reports Simon-Makuch plot with cumulative incidence of COVID-19, but has no extractable information (authors presented only the number of individuals at risk

			among all the groups of interest)
Sibbel et al.	Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis	Journal of the American Society of Nephrology	wrong intervention
Sibbel et al.	Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis	Journal of the American Society of Nephrology : JASN	wrong study duration
Silzle et al.	Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in patients with multiple myeloma three and six months after vaccination	Swiss Medical Weekly	wrong outcome
Singer et al.	Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study	EClinicalMedicine	wrong study duration
Singer et al.	Effectiveness of BNT162b2 mRNA COVID-19 Vaccine Against SARS-CoV-2 Variant Beta (B.1.351) Among Persons Identified Through Contact Tracing in Israel	Preprint - SSRN	wrong intervention
Singh et al.	Antibody Response after First-dose of ChAdOx1-nCOV (Covishield) and BBV-152 (Covaxin) amongst Health Care Workers in India: Preliminary Results of Cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) study	Preprint - medRxiv	wrong intervention
Skowronski & de Serres	Safety and efficacy of the BNT162B2 mRNA covid-19 vaccine	New England Journal of Medicine	wrong intervention
Skowronski et al.	Comparative single-dose mRNA and ChAdOx1 vaccine effectiveness against SARS-CoV-2, including variants of concern: test-negative design, British Columbia, Canada	The Journal of infectious diseases	wrong intervention
Smith et al.	Genomic and Virological Characterization of SARS-CoV-2 Variants in a Subset of Unvaccinated and Vaccinated U.S. Military Personnel	medRxiv	wrong population
Spensley et al.	Comparison of vaccine effectiveness against the Omicron (B.1.1.529) variant in patients receiving haemodialysis	medRxiv	wrong study duration
Spitzer et al.	Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel	JAMA	wrong comparator
Sritipsukho et al.	Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: A test-negative case-control study	Emerging microbes & infections	wrong study duration
Sritipsukho et al.	Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta	Emerging microbes & infections	wrong study duration

	variant-dominant pandemic: A test-negative case-control study		
Starrfelt et al.	Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: A national cohort study, January - September 2021	medRxiv	wrong comparator
Starrfelt et al.	Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, January ,Äi September 2021	medRxiv	wrong outcome
Starrfelt et al.	High vaccine effectiveness against COVID-19 infection and severe disease among residents and staff of long-term care facilities in Norway, November – June 2021	medRxiv	delayed exclusion - a cohort study, estimating vaccine effectiveness among residents and health care workers in long-term care facilities. COVID-19 vaccine effectiveness against infection, hospitalisation and death presented from Cox models in Tables 2 and 3 (but no information about individual level follow up; authors presented only person time at risk.
Stowe et al.	Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant	Hand search; Public Health England pre-prints	wrong intervention
Suah et al.	Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study	medRxiv	wrong outcome
Suah et al.	PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio	Vaccines	wrong outcome
Sultan et al.	Distinct Vaccine Efficacy Rates Among Health Care Workers During a COVID-19 Outbreak in Jordan	medRxiv	wrong outcome
Svoboda et al.	Safety and Efficacy of Sars-Cov-2 Vaccines in Hodgkin Lymphoma Patients Receiving PD-1 Inhibitors	Blood	wrong outcome
Swift et al.	Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare personnel	Clinical Infectious Diseases	wrong intervention
Tahor et al.	Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals	Nature Medicine	uplicated
Tande et al.	Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening	Clinical Infectious Diseases	wrong intervention

Tande et al.	mRNA Vaccine Effectiveness Against Asymptomatic SARS-CoV-2 Infection Over a Seven-Month Period	Infection Control and Hospital Epidemiology	wrong study design
Tang et al.	Asymptomatic and Symptomatic SARS-CoV-2 Infections after BNT162b2 Vaccination in a Routinely Screened Workforce	JAMA - Journal of the American Medical Association	wrong intervention
Tang et al.	BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar	Preprint - medRxiv	wrong study design
Tang et al.	BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar	Nature Medicine	duplicated
Tanislav et al.	Effect of SARS-CoV-2 vaccination among health care workers in a geriatric care unit after a B.1.1.7-variant outbreak	Public Health	wrong intervention
Taquet et al.	Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections	medRxiv	wrong outcome
Tartof et al.	Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study	SSRN	delayed exclusion - duplicate of Study ID 21-3
Tartof et al.	Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study	Lancet (London, England)	duplicated
Taubel et al.	Can a second booster dose be delayed in patients who have had COVID-19?	Preprint - medRxiv	wrong outcome
Tene et al.	Assessment of effectiveness of 1 dose of BNT162B2 vaccine for SARS-CoV-2 infection 13 to 24 days after immunization	JAMA network open	wrong intervention
Tene et al.	The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data	Clinical Infectious Diseases	wrong intervention
Tenforde et al.	Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States	Clinical Infectious Diseases	wrong study design
Tenforde et al.	Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021	MMWR. Morbidity and mortality weekly report	wrong study duration
Tenforde et al.	Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged $\geq$ 65 Years - United States, January-March 2021	Morbidity and Mortality Weekly Report	wrong intervention
Tenforde et al.	Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021	Morbidity and Mortality Weekly Report (MMWR) - CDC	delayed exclusion - case-control study, assessing vaccine effectiveness against hospitalization in a multistate

			network over 24 weeks. Vaccine effectiveness across diverse time points presented in Supplementary material (as figures, with no extractable information)
Thangaraj et al.	Predominance of delta variant among the COVID-19 vaccinated and unvaccinated individuals, India, May 2021	The Journal of Infection	wrong outcome
Thiruvengadam et al.	Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses	The Lancet. Infectious diseases	wrong study duration
Thiruvengadam et al.	Cellular Immune Responses are Preserved and May Contribute to ChAdOx1 nCoV-19 Vaccine Effectiveness Against Infection Due to SARS-CoV-2 B.1.617.2 Delta Variant Despite Reduced Virus Neutralisation	Preprint - SSRN	wrong intervention
Thomas et al.	Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial	Vaccine	wrong comparator
Thomas et al.	15580 COVID-19 vaccine in participants (ptcpts) with cancer: Subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine	Annals of Oncology	wrong outcome
Thomas et al.	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months	The New England journal of medicine	duplicated
Thomas et al.	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months	The New England Journal of Medicine	delayed exclusion - pre-print version of the article (the published version is included in the main document)
Thompson et al.	Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022	MMWR. Morbidity and mortality weekly report	wrong comparator
Thompson et al.	Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021	Morbidity and Mortality Weekly Report	wrong intervention

Thompson et al.	Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines	New England Journal of Medicine	wrong intervention
Thompson et al.	Effectiveness of covid-19 vaccines in ambulatory and inpatient care settings	New England Journal of Medicine	duplicated
Toback et al.	Safety, Immunogenicity, and Efficacy of a COVID-19 Vaccine (NVX-CoV2373) Co-administered With Seasonal Influenza Vaccines	Preprint - medRxiv	wrong intervention
Toker et al.	Vaccination status among patients with the need for emergency hospitalizations related to COVID-19	The American journal of emergency medicine	wrong comparator
Toniasso et al.	Reduction in COVID-19 prevalence in healthcare workers in a university hospital in southern Brazil after the start of vaccination	International Journal of Infectious Diseases: IJID	wrong intervention
Tran et al.	Efficacy of COVID-19 vaccination on the symptoms of patients with long COVID: a target trial emulation using data from the ComPaRe e-cohort in France	SSRN	wrong outcome
Trapani et al.	COVID-19 vaccines in patients with cancer	The Lancet Oncology	wrong publication type
Tré-Hardy et al.	Waning antibodies in SARS-CoV-2 naïve vaccines: Results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers	The Journal of Infection	wrong intervention
Tré-Hardy et al.	Six-month interim analysis of ongoing immunogenicity surveillance of the mRNA-1273 vaccine in healthcare workers: A third dose is expected	Journal of Infection	delayed exclusion - data mainly focusing on immunogenicity findings.
Tsapepas et al.	Clinically Significant COVID-19 Following SARS-CoV-2 Vaccination in Kidney Transplant Recipients	American Journal of Kidney Diseases	wrong outcome
Tseng et al.	Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants	Nature medicine	wrong comparator
Tseng et al.	Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants		delayed exclusion - baseline is 14-90 days, which is beyond our 30.5 days average post-receipt of second dose threshold
Tsiatis et al.	Estimating vaccine efficacy over time after a randomized study is unblinded	Biometrics	wrong study design
Tyagi et al.	Breakthrough COVID19 infections after vaccinations in healthcare and other workers in a chronic care medical facility in New Delhi, India	Diabetes & Metabolic Syndrome	wrong outcome
Uchner et al.	Breakthrough SARS-CoV-2 Infections after Vaccination in North Carolina	medRxiv	wrong outcome
Uzun et al.	COVID-19: vaccination vs. hospitalization	Infection	wrong outcome
Vahidy et al.	Real World Effectiveness of COVID-19 mRNA Vaccines against Hospitalizations and Deaths in the United States	Preprint - medRxiv	article withdrawn

Vaishya et al.	SARS-CoV-2 infection after COVID-19 immunization in healthcare workers: A retrospective, pilot study	The Indian Journal of Medical Research	NO PDF
Vasileiou et al.	Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study	The Lancet	wrong intervention
Vasileiou et al.	Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People	Hand search; Preprint - SSRN	wrong intervention
Vergnes	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine	The New England Journal of Medicine	wrong intervention
Victor et al.	Protective Effect of COVID-19 Vaccine Among Health Care Workers During the Second Wave of the Pandemic in India	Mayo Clinic proceedings	wrong intervention
Victoria et al.	Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality	EClinicalMedicine	wrong study design
Vijayasingham et al.	Sex-disaggregated data in COVID-19 vaccine trials	The Lancet	wrong study design
Villela et al.	Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases	medRxiv	wrong outcome
Vitek et al.	Vaccine effectiveness against severe acute respiratory infections (SARI) COVID-19 hospitalisations estimated from real-world surveillance data, Slovenia, October 2021	Eurosurveillance	wrong comparator
Vivaldi et al.	Correlation between post-vaccination titres of combined IgG, IgA, and IgM anti-Spike antibodies and protection against breakthrough SARS-CoV-2 infection: a population-based longitudinal study (COVIDENCE UK)	medRxiv	wrong comparator
Vokó et al.	Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study	Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases	wrong study duration
Voysey et al.	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK	The Lancet	wrong intervention
Voysey et al.	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1	The Lancet	wrong intervention



	nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials		
Wadei et al.	COVID-19 infection in solid organ transplant recipients after SARS-CoV-2 vaccination	American Journal of Transplantation	wrong intervention
Wagner et al.	COVID-19 vaccine: mRNA-1273 is effective and safe	Pneumologie	foreign language
Waldhorn et al.	Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors	Cancer discovery	wrong comparator
Waldhorn et al.	Six Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors	Cancer Discovery	delayed exclusion - data mainly focusing on immunogenicity findings. Also, study included only vaccinated individuals (no unvaccinated controls)
Wang et al.	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine	The New England Journal of Medicine	wrong intervention
Wang et al.	The impacts of COVID-19 vaccine timing, number of doses, and risk prioritization on mortality in the US	Preprint - medRxiv	wrong study design
Wang et al.	Increased risk for COVID-19 breakthrough infection in fully vaccinated patients with substance use disorders in the United States between December 2020 and August 2021	World Psychiatry	wrong comparator
Waxman et al.	Comparison of Natural and BNT162b2 Vaccine-induced Immunity, with and without an Enhancer or Booster Dose, on the Risk of COVID-19-Related Hospitalization in Israel	Research Square	wrong study duration
Westholter & Taube	SARS-CoV-2 outbreak in a long-term care facility after vaccination with BNT162b2	Clinical Infectious Diseases	wrong intervention
Whitaker et al.	Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups	The Journal of infection	wrong study duration
Whitaker et al.	Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups	Hand search - Public Health England preprints	wrong intervention
White et al.	Incident SARS-CoV-2 Infection among mRNA-Vaccinated and Unvaccinated Nursing Home Residents	The New England Journal of Medicine	wrong intervention
Wickert et al.	Estimates of Single Dose and Full Dose BNT162b2 Vaccine Effectiveness among USAF Academy cadets, 1 Mar - 1 May 2021	Preprint - medRxiv	wrong intervention
Williams et al.	Measuring vaccine efficacy against infection and disease in clinical trials: sources and magnitude of bias in COVID-19 vaccine efficacy estimates	Preprint - medRxiv	wrong intervention
Williams et al.	COVID-19 Outbreak Associated with a SARS-CoV-2 P.1 Lineage in a Long-Term Care Home	Hand search; Clinical Infectious Diseases	wrong intervention

	after Implementation of a Vaccination Program – Ontario, April-May 2021		
Wise et al.	Covid-19: New data on Oxford AstraZeneca vaccine backs 12 week dosing interval	BMJ (Clinical Research Ed.)	wrong publication type
Wise et al.	Covid-19: People who have had infection might only need one dose of mRNA vaccine	BMJ (Clinical Research Ed.)	wrong publication type
Wise et al.	Covid-19: People who have had infection might only need one dose of mRNA vaccine	BMJ (Clinical Research Ed.)	duplicate
Wise et al.	Covid-19: Pfizer BioNTech vaccine reduced cases by 94% in Israel, shows peer reviewed study	BMJ (Clinical Research Ed.)	wrong publication type
Wu et al.	1562MO Effectiveness of COVID-19 vaccination in cancer patients: A nationwide Veterans Affairs study	Annals of Oncology	wrong outcome
Xie et al.	Comparative effectiveness of the BNT162b2 vs ChAdOx1 vaccine against Covid-19	medRxiv	wrong comparator
Xiong et al.	Age and Gender Disparities in Adverse Events Following COVID-19 Vaccination: Real-World Evidence Based on Big Data for Risk Management	Frontiers in Medicine	wrong intervention
Yadav et al.	The high mortality and impact of vaccination on COVID-19 in hemodialysis population in India during the second wave	Kidney International Reports	wrong intervention
Yan et al.	Rate and risk factors for breakthrough SARS-CoV-2 infection after vaccination	Journal of Infection	wrong intervention
Yassi et al.	Infection control, occupational and public health measures including mRNA-based vaccination against SARS-CoV-2 infections to protect healthcare workers from variants of concern: a 14-month observational study using surveillance data	Preprint - medRxiv	wrong intervention
Yelin et al.	Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbidities	Preprint - medRxiv	wrong intervention
Young Xu	Effectiveness of mRNA COVID-19 Vaccines against Omicron among Veterans	medRxiv	wrong study duration
Young Xu et al.	Coverage and Effectiveness of mRNA COVID-19 Vaccines among Veterans	Preprint - medRxiv	wrong intervention
Young-Xu et al.	Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans	JAMA network open	wrong study duration
Yu Chen et al.	POS-977 RISK OF COVID-19 INFECTION POST VACCINATION PROGRAMME IN PATIENTS WITH END STAGE KIDNEY DISEASE IN PENANG STATE	Kidney International Reports	Full-text not found
Zacay et al.	BNT162b2 Vaccine Effectiveness in Preventing Asymptomatic Infection With SARS-CoV-2 Virus: A Nationwide Historical Cohort Study	Open Forum Infectious Diseases	wrong intervention

Zambrano et al.	Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021	MMWR. Morbidity and mortality weekly report	wrong outcome
Zaqout et al.	The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout	International Journal of Infectious Diseases: IJID	wrong intervention
Zheutlin et al.	Durability of Protection against COVID-19 Breakthrough Infections and Severe Disease by Vaccines in the United States	medRxiv	wrong comparator

## Appendix 6: Data-extraction template

<b>Vaccine product</b>	
Source	First author of study
Link	DOI or Pubmed ID
Date published	in format YYYY/MM/DD or preprint
Country	
Funding	public or industry
<b>Study details</b>	
Study type	RCT/cohort/data-linkage/test-negative/case-control/other
Surveillance	routine screening Y or N
Population(s)	general public/LTC/Households/HCW/Other
Control group	not vaccinated, <7day vaccinated internal control, none, other
Total (N)	number of all study participants
Female	number or %
LTC	number or %
HCW	number or %
Households	number or %
>80	number or %
>70	number or %
>60	number or %
<b>Outcomes</b>	outcomes separated by VOC type
Outcomes	confirmed infection/asymptomatic/mild symptomatic/severe symptoms/hospitalized/ICU/death
1st Dose VE	VE with 95% CI
Days post 1st dose	days post 1st dose when VE provided
2nd Dose VE	VE with 95% CI
Days post 2nd dose	days post 2nd dose when VE provided
Rates per X person-days/years	vaccinated vs control
HR	vaccinated vs control
RR	vaccinated vs control
Adjusted	Regression, stratification, matching and associated variables
<b>Transmission</b>	infection rates in unvaccinated contacts of vaccinated individuals